US20190119679A1 - METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA - Google Patents
METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA Download PDFInfo
- Publication number
- US20190119679A1 US20190119679A1 US16/229,821 US201816229821A US2019119679A1 US 20190119679 A1 US20190119679 A1 US 20190119679A1 US 201816229821 A US201816229821 A US 201816229821A US 2019119679 A1 US2019119679 A1 US 2019119679A1
- Authority
- US
- United States
- Prior art keywords
- seq
- exon
- mrna
- dmd
- oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1719—Muscle proteins, e.g. myosin or actin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/313—Phosphorodithioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Definitions
- the invention relates to the field of genetics, more specifically human genetics.
- the invention in particular relates to the modulation of splicing of the human Duchenne Muscular Dystrophy pre-mRNA.
- Myopathies are disorders that result in functional impairment of muscles.
- Muscular dystrophy refers to genetic diseases that are characterized by progressive weakness and degeneration of skeletal muscles.
- Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are the most common childhood forms of muscular dystrophy. They are recessive disorders and because the gene responsible for DMD and BMD resides on the X-chromosome, mutations mainly affect males with an incidence of about 1 in 3500 boys.
- DMD and BMD are caused by genetic defects in the DMD gene encoding dystrophin, a muscle protein that is required for interactions between the cytoskeleton and the extracellular matrix to maintain muscle fiber stability during contraction.
- DMD is a severe, lethal neuromuscular disorder resulting in a dependency on wheelchair support before the age of 12 and DMD patients often die before the age of thirty due to respiratory- or heart failure. In contrast, BMD patients often remain ambulatory until later in life, and have near normal life expectancies.
- DMD mutations in the DMD gene are mainly characterized by frame shifting insertions or deletions or nonsense point mutations, resulting in the absence of functional dystrophin. BMD mutations in general keep the reading frame intact, allowing synthesis of a partly functional dystrophin.
- DMD Duchenne muscular dystrophy
- AONs antisense oligonucleotides interfering with splicing signals the skipping of specific exons can be induced in the DMD pre-mRNA, thus restoring the open reading frame and converting the severe DMD into a milder BMD phenotype (van Deutekom et al. Hum Mol Genet. 2001; 10: 1547-54; Aartsma-Rus et al., Hum Mol Genet 2003; 12(8)907-14.). In vivo proof-of-concept was first obtained in the mdx mouse model, which is dystrophin-deficient due to a nonsense mutation in exon 23.
- Intramuscular and intravenous injections of AONs targeting the mutated exon 23 restored dystrophin expression for at least three months (Lu et al. Nat Med. 2003; 8: 1009-14; Lu et al., Proc Natl Acad Sci U S A. 2005;102(1)198-203). This was accompanied by restoration of dystrophin-associated proteins at the fiber membrane as well as functional improvement of the treated muscle.
- In vivo skipping of human exons has also been achieved in the hDMD mouse model, which contains a complete copy of the human DMD gene integrated in chromosome 5 of the mouse (Bremmer-Bout et al. Molecular Therapy. 2004; 10: 232-40; 't Hoen et al. J Biol Chem. 2008; 283: 5899-907).
- Therapeutic skipping of exon 45 of the DMD pre-mRNA would restore the open reading frame of DMD patients having deletions including but not limited to exons 12-44, 18-44, 44, 46, 46-47, 46-48, 46-49, 46-51, 46-53, 46-55, 46-59, 46-60 of the DMD pre-mRNA, occurring in a total of 16% of all DMD patients with a deletion (Aartsma-Rus and van Deutekom, 2007, Antisense Elements (Genetics) Research Focus, 2007 Nova Science Publishers, Inc). Furthermore, for some DMD patients the simultaneous skipping of one of more exons in addition to exon 45, such as exons 51 or 53 is required to restore the correct reading frame. None-limiting examples include patients with a deletion of exons 46-50 requiring the co-skipping of exons 45 and 51, or with a deletion of exons 46-52 requiring the co-skipping of exons 45 and 53.
- the invention provides a method for inducing and/or promoting skipping of exon 45 of DMD pre-mRNA in a patient, preferably in an isolated cell of said patient, the method comprising providing said cell and/or said patient with a molecule that binds to a continuous stretch of at least 21 nucleotides within said exon.
- a method for inducing and/or promoting skipping of exon 45 of DMD pre-mRNA, preferably in an isolated cell of a patient, the method comprising providing said cell and/or said patient with a molecule that binds to a continuous stretch of at least 21 nucleotides within said exon.
- a DMD pre-mRNA preferably means the pre-mRNA of a DMD gene of a DMD or BMD patient.
- the DMD gene or protein corresponds to the dystrophin gene or protein.
- a patient is preferably intended to mean a patient having DMD or BMD as later defined herein or a patient susceptible to develop DMD or BMD due to his or her genetic background.
- Exon skipping refers to the induction in a cell of a mature mRNA that does not contain a particular exon that is normally present therein. Exon skipping is achieved by providing a cell expressing the pre-mRNA of said mRNA with a molecule capable of interfering with sequences such as, for example, the splice donor or splice acceptor sequence that are both required for allowing the enzymatic process of splicing, or a molecule that is capable of interfering with an exon inclusion signal required for recognition of a stretch of nucleotides as an exon to be included in the mRNA.
- the term pre-mRNA refers to a non-processed or partly processed precursor mRNA that is synthesized from a DNA template in the cell nucleus by transcription.
- inducing anchor promoting skipping of an exon means that at least 1%, 10%, 20%, 30%, 40%,50%, 60%, 70%, 80%, 90% or more of the DMD mRNA in one or more (muscle) cells of a treated patient will not contain said exon. This is preferably assessed by PCR as described in the examples.
- a method of the invention by inducing or promoting skipping of exon 45 of the DMD pre-mRNA in one or more cells of a patient provides said patient with a functional dystrophin protein and/or decreases the production of an aberrant dystrophin protein in said patient. Therefore a preferred method is a method, wherein a patient or a cell of said patient is provided with a functional dystrophin protein and/or wherein the production of an aberrant dystrophin protein in said patient or in a cell of said patient is decreased
- Decreasing the production of an aberrant dystrophin may be assessed at the mRNA level and preferably means that 99%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5% or less of the initial amount of aberrant dystrophin mRNA, is still detectable by RT PCR.
- An aberrant dystrophin mRNA or protein is also referred to herein as a non-functional dystrophin mRNA or protein.
- a non functional dystrophin protein is preferably a dystrophin protein which is not able to bind actin and/or members of the DGC protein complex.
- a non-functional dystrophin protein or dystrophin mRNA does typically not have, or does not encode a dystrophin protein with an intact C-terminus of the protein.
- Increasing the production of a functional dystrophin in said patient or in a cell of said patient may be assessed at the mRNA level (by RT-PCR analysis) and preferably means that a detectable amount of a functional dystrophin mRNA is detectable by RT PCR.
- 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more of the detectable dystrophin mRNA is a functional dystrophin mRNA.
- Increasing the production of a functional dystrophin in said patient or in a cell of said patient may be assessed at the protein level (by immuno fluorescence and western blot analyses) and preferably means that a detectable amount of a functional dystrophin protein is detectable by immunofluorescence or western blot analysis.
- 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more of the detectable dystrophin protein is a functional dystrophin protein.
- a functional dystrophin is preferably a wild type dystrophin corresponding to a protein having the amino acid sequence as identified in SEQ ID NO: 1.
- a functional dystrophin is preferably a dystrophin, which has an actin binding domain in its N terminal part (first 240 amino acids at the N terminus), a cystein-rich domain (amino acid 3361 till 3685) and a C terminal domain (last 325 amino acids at the C terminus) each of these domains being present in a wild type dystrophin as known to the skilled person.
- the amino acids indicated herein correspond to amino acids of the wild type dystrophin being represented by SEQ ID NO:l.
- a functional dystrophin is a dystrophin which exhibits at least to some extent an activity of a wild type dystrophin. “At least to some extent” preferably means at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 100% of a corresponding activity of a wild type functional dystrophin.
- an activity of a functional dystrophin is preferably binding to actin and to the dystrophin-associated glycoprotein complex (DGC) (Aartsma-Rus A et al, (2006), Entries in the leiden Duchenne Muscular Dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule, Muscle Nerve, 34: 135-144). Binding of dystrophin to actin and to the DGC complex may be visualized by either co-immunoprecipitation using total protein extracts or immunofluorescence analysis of cross-sections, from a muscle biopsy, as known to the skilled person.
- DGC dystrophin-associated glycoprotein complex
- Duchenne muscular dystrophy typically have a mutation in the DMD gene that prevent synthesis of the complete dystrophin protein, i.e of a premature stop prevents the synthesis of the C-terminus.
- the DMD gene also comprises a mutation compared to the wild type gene but the mutation does typically not induce a premature stop and the C-terminus is typically synthesized.
- a functional dystrophin protein is synthesized that has at least the same activity in kind as the wild type protein, not although not necessarily the same amount of activity.
- the genome of a BMD individual typically encodes a dystrophin protein comprising the N terminal part (first 240 amino acids at the N terminus), a cystein-rich domain (amino acid 3361 till 3685) and a C terminal domain (last 325 amino acids at the C terminus) but its central rod shaped domain may be shorter than the one of a wild type dystrophin (Aartsma-Rus A et al, (2006), Entries in the leiden Duchenne Muscular Dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule, Muscle Nerve, 34: 135-144).
- Exon—skipping for the treatment of DMD is typically directed to overcome a premature stop in the pre-mRNA by skipping an exon in the rod-shaped domain to correct the reading frame and allow synthesis of the remainder of the dystrophin protein including the C-terminus, albeit that the protein is somewhat smaller as a result of a smaller rod domain.
- an individual having DMD and being treated by a method as defined herein will be provided a dystrophin which exhibits at least to some extent an activity of a wild type dystrophin.
- a functional dystrophin is a dystrophin of an individual having BMD: typically said dystrophin is able to interact with both actin and the DGC, but its central rod shaped domain may be shorter than the one of a wild type dystrophin (Aartsma-Rus A et al, (2006), Entries in the leiden Duchenne Muscular Dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule, Muscle Nerve, 34: 135-144).
- the central rod-shaped domain of wild type dystrophin comprises 24 spectrin-like repeats (Aartsma-Rus A et al, (2006), Entries in the leiden Duchenne Muscular Dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule, Muscle Nerve, 34: 135-144).
- a central rod-shaped domain of a dystrophin as provided herein may comprise 5 to 23, 10 to 22 or 12 to 18 spectrin-like repeats as long as it can bind to actin and to DGC.
- a method of the invention may alleviate one or more characteristics of a muscle cell from a DMD patient comprising deletions including but not limited to exons 12-44, 18-44, 44, 46, 46-47, 46-48, 46-49, 46-51, 46-53, 46-55, 46 - 59, 46 - 60 of the DMD pre-mRNA of said patient (Aartsma-Rus and van Deutekom, 2007, Antisense Elements (Genetics) Research Focus, 2007 Nova Science Publishers, Inc) as well as from DMD patients requiring the simultaneous skipping of one of more exons in addition to exon 45 including but not limited to patients with a deletion of exons 46-50 requiring the co-skipping of exons 45 and 51, or with a deletion of exons 46-52 requiring the co-skipping of exons 45 and 53.
- one or more symptom(s) or characteristic(s) of a myogenic cell or muscle cell from a DMD patient is/are alleviated. Such symptoms or characteristics may be assessed at the cellular, tissue level or on the patient self.
- An alleviation of one or more symptoms or characteristics may be assessed by any of the following assays on a myogenic cell or muscle cell from a patient: reduced calcium uptake by muscle cells, decreased collagen synthesis, altered morphology, altered lipid biosynthesis, decreased oxidative stress, and/or improved muscle fiber function, integrity, and/or survival. These parameters are usually assessed using immunofluorescence and/or histochemical analyses of cross sections of muscle biopsies.
- the improvement of muscle fiber function, integrity and/or survival may also be assessed using at least one of the following assays: a detectable decrease of creatine kinase in blood, a detectable decrease of necrosis of muscle fibers in a biopsy cross-section of a muscle suspected to be dystrophic, and/or a detectable increase of the homogeneity of the diameter of muscle fibers in a biopsy cross-section of a muscle suspected to be dystrophic.
- a detectable decrease of creatine kinase in blood a detectable decrease of necrosis of muscle fibers in a biopsy cross-section of a muscle suspected to be dystrophic
- a detectable increase of the homogeneity of the diameter of muscle fibers in a biopsy cross-section of a muscle suspected to be dystrophic are known to the skilled person.
- Creatine kinase may be detected in blood as described in Hodgetts et al (Hodgetts S., et al, (2006), Neuromuscular Disorders, 16: 591-602.2006).
- a detectable decrease in creatine kinase may mean a decrease of 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more compared to the concentration of creatine kinase in a same DMD patient before treatment.
- a detectable decrease of necrosis of muscle fibers is preferably assessed in a muscle biopsy, more preferably as described in Hodgetts et al (Hodgetts S., et al, (2006), Neuromuscular Disorders, 16: 591-602.2006) using biopsy cross-sections.
- a detectable decrease of necrosis may be a decrease of 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more of the area wherein necrosis has been identified using biopsy cross-sections. The decrease is measured by comparison to the necrosis as assessed in a same DMD patient before treatment.
- a detectable increase of the homogeneity of the diameter of muscle fibers is preferably assessed in a muscle biopsy cross-section, more preferably as described in Hodgetts et al (Hodgetts S., et al, (2006), Neuromuscular Disorders, 16: 591-602.2006). The increase is measured by comparison to the homogeneity of the diameter of muscle fibers in a muscle biopsy cross-section of a same DMD patient before treatment.
- An alleviation of one or more symptoms or characteristics may be assessed by any of the following assays on the patient self: prolongation of time to loss of walking, improvement of muscle strength, improvement of the ability to lift weight, improvement of the time taken to rise from the floor, improvement in the nine-meter walking time, improvement in the time taken for four-stairs climbing, improvement of the leg function grade, improvement of the pulmonary function, improvement of cardiac function, improvement of the quality of life.
- assays is known to the skilled person.
- Detectable improvement or prolongation is preferably a statistically significant improvement or prolongation as described in Hodgetts et al (Hodgetts S., et al, (2006), Neuromuscular Disorders, 16: 591-602.2006).
- the alleviation of one or more symptom(s) of Duchenne Muscular Dystrophy may be assessed by measuring an improvement of a muscle fiber function, integrity and/or survival as later defined herein.
- a treatment in a method according to the invention may have a duration of at least one week, at least one month, at least several months, at least one year, at least 2, 3, 4, 5, 6 years or more.
- the frequency of administration of an oligonucleotide, composition, compound of the invention may depend on several parameters such as the age of the patient, the type of mutation, the number of molecules (dose), the formulation of said molecule.
- the frequency may be ranged between at least once in a two weeks, or three weeks or four weeks or five weeks or a longer time period.
- Each molecule or oligonucleotide or equivalent thereof as defined herein for use according to the invention may be suitable for direct administration to a cell, tissue and/or an organ in vivo of individuals affected by or at risk of developing DMD and may be administered directly in vivo, ex vivo or in vitro.
- An oligonucleotide as used herein may be suitable for administration to a cell, tissue and/or an organ in vivo of individuals affected by or at risk of developing DMD, and may be administered in vivo, ex vivo or in vitro.
- Said oligonucleotide may be directly or indirectly administrated to a cell, tissue and/or an organ in vivo of an individual affected by or at risk of developing DMD, and may be administered directly or indirectly in vivo, ex vivo or in vitro.
- Duchenne muscular dystrophy has a pronounced phenotype in muscle cells
- said cells are muscle cells
- said tissue is a muscular tissue
- said organ comprises or consists of a muscular tissue.
- a preferred organ is the heart.
- said cells comprise a gene encoding a mutant dystrophin protein.
- said cells are cells of an individual suffering from DMD.
- a molecule or oligonucleotide or equivalent thereof can be delivered as is to a cell.
- a solution that is compatible with the delivery method.
- the solution is a physiological salt solution.
- an excipient that will further enhance delivery of said molecule, oligonucleotide or functional equivalent thereof as defined herein, to a cell and into a cell, preferably a muscle cell.
- Preferred excipient are defined in the section entitled “pharmaceutical composition”.
- an additional molecule is used which is able to induce and/or promote skipping of a distinct exon of the DMD pre-mRNA of a patient.
- the second exon is selected from: exon 7, 44, 46, 51, 53, 59, 67 of the dystrophin pre-mRNA of a patient.
- Molecules which can be used are depicted in table 2.
- Preferred molecules comprise or consist of any of the oligonucleotides as disclosed in table 2. Several oligonucleotides may also be used in combination.This way, inclusion of two or more exons of a DMD pre-mRNA in mRNA produced from this pre-mRNA is prevented.
- This embodiment is further referred to as double- or multi-exon skipping (Aartsma-Rus A, Janson A A, Kaman W E, et al. Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. Am J Hum Genet 2004;74(1):83-92, Aartsma-Rus A, Kaman W E, Weij R, den Dunnen J T, van Ommen G J, van Deutekom J C. Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons. Mol Ther 2006;14(3):401-7). In most cases double-exon skipping results in the exclusion of only the two targeted exons from the dystrophin pre-mRNA.
- stretches of nucleotides complementary to at least two dystrophin exons are separated by a linking moiety.
- the at least two stretches of nucleotides are thus linked in this embodiment so as to form a single molecule.
- said compounds can be administered to an individual in any order.
- said compounds are administered simultaneously (meaning that said compounds are administered within 10 hours, preferably within one hour). This is however not necessary.
- said compounds are administered sequentially.
- This molecule preferably comprises or consists of an oligonucleotide, Said oligonucleotide is preferably an antisense oligonucleotide (AON) or antisense oligoribonucleotide.
- AON antisense oligonucleotide
- exon 45 is specifically skipped at a high frequency using a molecule that binds to a continuous stretch of at least 21 nucleotides within said exon.
- this effect can be associated with a higher binding affinity of said molecule, compared to a molecule that binds to a continuous stretch of less than 21 nucleotides, there could be other intracellular parameters involved that favor thermodynamic, kinetic, or structural characteristics of the hybrid duplex.
- a molecule that binds to a continuous stretch of at least 21, 25, 30, 35, 40, 45, 50 nucleotides within said exon is used.
- a molecule or an oligonucleotide of the invention which comprises a sequence that is complementary to a part of exon 45 of DMD pre-mRNA is such that the complementary part is at least 50% of the length of the oligonucleotide of the invention, more preferably at least 60%, even more preferably at least 70%, even more preferably at least 80%, even more preferably at least 90% or even more preferably at least 95%, or even more preferably 98% and most preferably up to 100%.
- “A part of exon 45” preferably means a stretch of at least 21 nucleotides.
- an oligonucleotide of the invention consists of a sequence that is complementary to part of exon 45 dystrophin pre-mRNA as defined herein.
- an oligonucleotide may comprise a sequence that is complementary to part of exon 45 dystrophin pre-mRNA as defined herein and additional flanking sequences.
- the length of said complementary part of said oligonucleotide is of at least 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 nucleotides.
- flanking sequences may be used.
- flanking sequences are used to modify the binding of a protein to said molecule or oligonucleotide, or to modify a thermodynamic property of the oligonucleotide, more preferably to modify target RNA binding affinity.
- additional flanking sequences are complementary to sequences of the DMD pre-mRNA which are not present in exon 45.
- flanking sequences are preferably complementary to sequences comprising or consisting of the splice site acceptor or donor consensus sequences of exon 45.
- flanking sequences are complementary to sequences comprising or consisting of sequences of an intron of the DMD pre-mRNA which is adjacent to exon 45; i.e. intron 44 or 45.
- a continuous stretch of at least 21, 25, 30, 35, 40, 45, 50 nucleotides within exon 45 is preferably selected from the sequence:
- a molecule that binds to a nucleotide sequence comprising or consisting of a continuous stretch of at least 21, 25, 30, 35, 40, 45, 50 nucleotides of SEQ ID NO. 2 results in highly efficient skipping of exon 45 in a cell provided with this molecule.
- Molecules that bind to a nucleotide sequence comprising a continuous stretch of less than 21 nucleotides of SEQ ID NO:2 were found to induce exon skipping in a less efficient way than the molecules of the invention. Therefore, in a preferred embodiment, a method is provided wherein a molecule binds to a continuous stretch of at least 21, 25, 30, 35 nucleotides within SEQ ID NO:2.
- the inventors surprisingly found that a higher specificity and efficiency of exon skipping may be reached using an oligonucleotides having a length of at least 21 nucleotides. None of the indicated sequences is derived from conserved parts of splice-junction sites. Therefore, said molecule is not likely to mediate differential splicing of other exons from the DMD pre-mRNA or exons from other genes.
- a molecule of the invention capable of interfering with the inclusion of exon 45 of the DMD pre-mRNA is a compound molecule that binds to the specified sequence, or a protein such as an RNA-binding protein or a non-natural zinc-finger protein that has been modified to be able to bind to the indicated nucleotide sequence on a RNA molecule.
- Methods for screening compound molecules that bind specific nucleotide sequences are for example disclosed in PCT/NL01/00697 and US patent 6875736, which are herein enclosed by reference.
- Methods for designing RNA-binding Zinc-finger proteins that bind specific nucleotide sequences are disclosed by Friesen and Darby, Nature Structural Biology 5: 543-546 (1998) which is herein enclosed by reference.
- a molecule of the invention capable of interfering with the inclusion of exon 45 of the DMD pre-mRNA comprises an antisense oligonucleotide that is complementary to and can base-pair with the coding strand of the pre-mRNA of the DMD gene.
- Said antisense oligonucleotide preferably contains a RNA residue, a DNA residue, and/or a nucleotide analogue or equivalent, as will be further detailed herein below.
- a preferred molecule of the invention comprises a nucleotide-based or nucleotide or an antisense oligonucleotide sequence of between 21 and 50 nucleotides or bases, more preferred between 21 and 40 nucleotides, more preferred between 21 and 30 nucleotides, such as 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, 25 nucleotides, 26 nucleotides, 27 nucleotides, 28 nucleotides, 29 nucleotides, 30 nucleotides, 31 nucleotides, 32 nucleotides, 33 nucleotides, 34 nucleotides, 35 nucleotides, 36 nucleotides, 37 nucleotides, 38 nucleotides, 39 nucleotides, 40 nucleotides, 41 nucleotides, 42 nucleotides, 43 nucleotides, 44 nucleotides, 45 nucleotides, 46 nucle
- a most preferred molecule of the invention comprises a nucleotide-based sequence of 25 nucleotides.
- a molecule of the invention binds to a continuous stretch of or is complementary to or is antisense to at least a continuous stretch of at least 21 nucleotides within the nucleotide sequence SEQ ID NO:2.
- the invention provides a molecule comprising or consisting of an antisense nucleotide sequence selected from the antisense nucleotide sequences as depicted in Table 1, except SEQ ID NO:68.
- a molecule of the invention that is antisense to the sequence of SEQ ID NO 2, which is present in exon 45 of the DMD gene preferably comprises or consists of the antisense nucleotide sequence of SEQ ID NO 3; SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO 7, SEQ ID NO 8, SEQ ID NO 9, SEQ ID NO 10, SEQ ID NO 11, SEQ ID NO 12, SEQ ID NO 13, SEQ ID NO 14, SEQ ID NO 15, SEQ ID NO 16, SEQ ID NO 17, SEQ ID NO 18, SEQ ID NO 19, SEQ ID NO 20, SEQ ID NO 21, SEQ ID NO 22, SEQ ID NO 23, SEQ ID NO 24, SEQ ID NO 25, SEQ ID NO 26, SEQ ID NO 27, SEQ ID NO 28, SEQ ID NO 29, SEQ ID NO 30, SEQ ID NO 31, SEQ ID NO 3,
- the invention provides a molecule comprising or consisting of the antisense nucleotide sequence of SEQ ID NO 3; SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO 7 and/or SEQ ID NO 8.
- the invention provides a molecule comprising or consisting of the antisense nucleotide sequence of SEQ ID NO 3. It was found that this molecule is very efficient in modulating splicing of exon 45 of the DMD pre-mRNA in a muscle cell.
- a nucleotide sequence of a molecule of the invention may contain a RNA residue, a DNA residue, a nucleotide analogue or equivalent as will be further detailed herein below.
- a molecule of the invention may encompass a functional equivalent of a molecule of the invention as defined herein.
- a molecule of the invention comprises a or at least one residue that is modified to increase nuclease resistance, and/or to increase the affinity of the antisense nucleotide for the target sequence. Therefore, in a preferred embodiment, an antisense nucleotide sequence comprises a or at least one nucleotide analogue or equivalent, wherein a nucleotide analogue or equivalent is defined as a residue having a modified base, and/or a modified backbone, and/or a non-natural internucleoside linkage, or a combination of these modifications.
- a nucleotide analogue or equivalent comprises a modified backbone.
- backbones are provided by morpholino backbones, carbamate backbones, siloxane backbones, sulfide, sulfoxide and sulfone backbones, formacetyl and thioformacetyl backbones, methyleneformacetyl backbones, riboacetyl backbones, alkene containing backbones, sulfamate, sulfonate and sulfonamide backbones, methyleneimino and methylenehydrazino backbones, and amide backbones.
- Phosphorodiamidate morpholino oligomers are modified backbone oligonucleotides that have previously been investigated as antisense agents.
- Morpholino oligonucleotides have an uncharged backbone in which the deoxyribose sugar of DNA is replaced by a six membered ring and the phosphodiester linkage is replaced by a phosphorodiamidate linkage.
- Morpholino oligonucleotides are resistant to enzymatic degradation and appear to function as antisense agents by arresting translation or interfering with pre-mRNA splicing rather than by activating RNase H.
- Morpholino oligonucleotides have been successfully delivered to tissue culture cells by methods that physically disrupt the cell membrane, and one study comparing several of these methods found that scrape loading was the most efficient method of delivery; however, because the morpholino backbone is uncharged, cationic lipids are not effective mediators of morpholino oligonucleotide uptake in cells. A recent report demonstrated triplex formation by a morpholino oligonucleotide and, because of the non-ionic backbone, these studies showed that the morpholino oligonucleotide was capable of triplex formation in the absence of magnesium.
- the linkage between a residue in a backbone does not include a phosphorus atom, such as a linkage that is formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages.
- a preferred nucleotide analogue or equivalent comprises a Peptide Nucleic Acid (PNA), having a modified polyamide backbone (Nielsen, et al. (1991) Science 254, 1497-1500). PNA-based molecules are true mimics of DNA molecules in terms of base-pair recognition.
- the backbone of the PNA is composed of N-(2-aminoethyl)-glycine units linked by peptide bonds, wherein the nucleobases are linked to the backbone by methylene carbonyl bonds.
- An alternative backbone comprises a one-carbon extended pyrrolidine PNA monomer (Govindaraju and Kumar (2005) Chem. Commun, 495-497).
- PNA-RNA hybrids are usually more stable than RNA-RNA or RNA-DNA hybrids, respectively (Egholm et al (1993) Nature 365, 566-568).
- a further preferred backbone comprises a morpholino nucleotide analog or equivalent, in which the ribose or deoxyribose sugar is replaced by a 6-membered morpholino ring.
- a most preferred nucleotide analog or equivalent comprises a phosphorodiamidate morpholino oligomer (PMO), in which the ribose or deoxyribose sugar is replaced by a 6-membered morpholino ring, and the anionic phosphodiester linkage between adjacent morpholino rings is replaced by a non-ionic phosphorodiamidate linkage.
- PMO phosphorodiamidate morpholino oligomer
- a nucleotide analogue or equivalent of the invention comprises a substitution of at least one of the non-bridging oxygens in the phosphodiester linkage. This modification slightly destabilizes base-pairing but adds significant resistance to nuclease degradation.
- a preferred nucleotide analogue or equivalent comprises phosphorothioate, chiral phosphorothioate, phosphorodithioate, phosphotriester, aminoalkylphosphotriester, H-phosphonate, methyl and other alkyl phosphonate including 3′-alkylene phosphonate, 5′-alkylene phosphonate and chiral phosphonate, phosphinate, phosphoramidate including 3′-amino phosphoramidate and aminoalkylphosphoramidate, thionophosphoramidate, thionoalkylphosphonate, thionoalkylphosphotriester, selenophosphate or boranophosphate.
- a further preferred nucleotide analogue or equivalent of the invention comprises one or more sugar moieties that are mono- or disubstituted at the 2′, 3′ and/or 5′ position such as a —OH; —F; substituted or unsubstituted, linear or branched lower (C1-C10) alkyl, alkenyl, alkynyl, alkaryl, allyl, aryl, or aralkyl, that may be interrupted by one or more heteroatoms; O—, S—, or N-alkyl; O—, S—, or N-alkenyl; O—, S-or N-alkynyl; O—, S—, or N-allyl; O-alkyl-O-alkyl, -methoxy, -aminopropoxy; aminoxy, methoxyethoxy; -dimethylaminooxyethoxy; and -dimethylaminoethoxyethoxy.
- the sugar moiety can be a pyranose or derivative thereof, or a deoxypyranose or derivative thereof, preferably a ribose or a derivative thereof, or deoxyribose or derivative thereof.
- Such preferred derivatized sugar moieties comprise Locked Nucleic Acid (LNA), in which the 2′-carbon atom is linked to the 3′ or 4′ carbon atom of the sugar ring thereby forming a bicyclic sugar moiety.
- LNA Locked Nucleic Acid
- a preferred LNA comprises 2′-O,4′-C-ethylene-bridged nucleic acid (Morita et al. 2001. Nucleic Acid Res Supplement No. 1: 241-242). These substitutions render the nucleotide analogue or equivalent RNase H and nuclease resistant and increase the affinity for the target RNA.
- an antisense oligonucleotide of the invention has at least two different types of analogues or equivalents.
- a preferred antisense oligonucleotide according to the invention comprises a 2′-O -alkyl phosphorothioate antisense oligonucleotide, such as 2′-O-methyl modified ribose (RNA), 2′-O-ethyl modified ribose, 2′-O-propyl modified ribose, and/or substituted derivatives of these modifications such as halogenated derivatives.
- RNA 2′-O-methyl modified ribose
- 2′-O-ethyl modified ribose 2′-O-propyl modified ribose
- substituted derivatives of these modifications such as halogenated derivatives.
- a most preferred antisense oligonucleotide according to the invention comprises a 2′-O-methyl phosphorothioate ribose.
- a functional equivalent of a molecule of the invention may be defined as an oligonucleotide as defined herein wherein an activity of said functional equivalent is retained to at least some extent.
- an activity of said functional equivalent is inducing exon 45 skipping and providing a functional dystrophin protein.
- Said activity of said functional equivalent is therefore preferably assessed by detection of exon 45 skipping and quantifying the amount of a functional dystrophin protein.
- a functional dystrophin is herein preferably defined as being a dystrophin able to bind actin and members of the DGC protein complex.
- the assessment of said activity of an oligonucleotide is preferably done by RT-PCR or by immunofluorescence or Western blot analysis.
- Said activity is preferably retained to at least some extent when it represents at least 50%, or at least 60%, or at least 70% or at least 80% or at least 90% or at least 95% or more of corresponding activity of said oligonucleotide the functional equivalent derives from.
- oligonucleotide when used it may be replaced by a functional equivalent thereof as defined herein.
- distinct antisense oligonucleotides can be combined for efficiently skipping of exon 45 of the human DMD pre-mRNA.
- a combination of at least two antisense oligonucleotides are used in a method of the invention, such as two distinct antisense oligonucleotides, three distinct antisense oligonucleotides, four distinct antisense oligonucleotides, or five distinct antisense oligonucleotides or even more. It is also encompassed by the present invention to combine several oligonucleotides or molecules as depicted in table 1 except SEQ ID NO:68.
- An antisense oligonucleotide can be linked to a moiety that enhances uptake of the antisense oligonucleotide in cells, preferably myogenic cells or muscle cells.
- moieties are cholesterols, carbohydrates, vitamins, biotin, lipids, phospholipids, cell-penetrating peptides including but not limited to antennapedia, TAT, transportan and positively charged amino acids such as oligoarginine, poly-arginine, oligolysine or polylysine, antigen-binding domains such as provided by an antibody, a Fab fragment of an antibody, or a single chain antigen binding domain such as a cameloid single domain antigen-binding domain.
- a preferred antisense oligonucleotide comprises a peptide-linked PMO.
- a preferred antisense oligonucleotide comprising one or more nucleotide analogs or equivalents of the invention modulates splicing in one or more muscle cells, including heart muscle cells, upon systemic delivery.
- systemic delivery of an antisense oligonucleotide comprising a specific nucleotide analog or equivalent might result in targeting a subset of muscle cells, while an antisense oligonucleotide comprising a distinct nucleotide analog or equivalent might result in targeting of a different subset of muscle cells. Therefore, in one embodiment it is preferred to use a combination of antisense oligonucleotides comprising different nucleotide analogs or equivalents for modulating skipping of exon 45 of the human DMD pre-mRNA.
- a cell can be provided with a molecule capable of interfering with essential sequences that result in highly efficient skipping of exon 45 of the human DMD pre-mRNA by plasmid-derived antisense oligonucleotide expression or viral expression provided by viral-based vector.
- a viral-based vector comprises an expression cassette that drives expression of an antisense molecule as defined herein.
- Preferred virus-based vectors include adenovirus- or adeno-associated virus-based vectors. Expression is preferably driven by a polymerase III promoter, such as a U1, a U6, or a U7 RNA promoter.
- a muscle or myogenic cell can be provided with a plasmid for antisense oligonucleotide expression by providing the plasmid in an aqueous solution.
- a plasmid can be provided by transfection using known transfection agentia such as, for example, LipofectAMINETM 2000 (Invitrogen) or polyethyleneimine (PEI; ExGen500 (MBI Fermentas)), or derivatives thereof.
- AAV adenovirus associated virus
- a preferred AAV-based vector comprises an expression cassette that is driven by a polymerase III-promoter (Pol III).
- Pol III polymerase III-promoter
- a preferred Pol III promoter is, for example, a U1, a U6, or a U7 RNA promoter.
- the invention therefore also provides a viral-based vector, comprising a Pol III-promoter driven expression cassette for expression of one or more antisense sequences of the invention for inducing skipping of exon 45 of the human DMD pre-mRNA.
- a molecule or a vector expressing an antisense oligonucleotide of the invention can be incorporated into a pharmaceutically active mixture or composition by adding a pharmaceutically acceptable carrier.
- the invention provides a composition, preferably a pharmaceutical composition comprising a molecule comprising an antisense oligonucleotide according to the invention, and/or a viral-based vector expressing the antisense sequence(s) according to the invention and a pharmaceutically acceptable carrier.
- a preferred pharmaceutical composition comprises a molecule as defined herein and/or a vector as defined herein, and a pharmaceutical acceptable carrier or excipient, optionally combined with a molecule and/or a vector which is able to modulate skipping of exon 7, 44, 46, 51, 53, 59, 67 of the DMD pre-mRNA.
- Preferred excipients include excipients capable of forming complexes, vesicles and/or liposomes that deliver such a molecule as defined herein, preferably an oligonucleotide complexed or trapped in a vesicle or liposome through a cell membrane. Many of these excipients are known in the art.
- Suitable excipients comprise polyethylenimine and derivatives, or similar cationic polymers, including polypropyleneimine or polyethylenimine copolymers (PECs) and derivatives, synthetic amphiphils, lipofectinTM, DOTAP and/or viral capsid proteins that are capable of self assembly into particles that can deliver such molecule, preferably an oligonucleotide as defined herein to a cell, preferably a muscle cell.
- PECs polypropyleneimine or polyethylenimine copolymers
- synthetic amphiphils synthetic amphiphils
- lipofectinTM lipofectinTM
- DOTAP DOTAP
- viral capsid proteins that are capable of self assembly into particles that can deliver such molecule, preferably an oligonucleotide as defined herein to a cell, preferably a muscle cell.
- excipients have been shown to efficiently deliver (oligonucleotide such as antisense) nucleic acids to a wide
- PEI polyethylenimine
- ExGen500 MBI Fermentas
- MBI Fermentas polyethylenimine
- Their high transfection potential is combined with an excepted low to moderate toxicity in terms of overall cell survival.
- the ease of structural modification can be used to allow further modifications and the analysis of their further (in vivo) nucleic acid transfer characteristics and toxicity.
- Lipofectin represents an example of a liposomal transfection agent. It consists of two lipid components, a cationic lipid N-[1-(2,3 dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA) (cp. DOTAP which is the methylsulfate salt) and a neutral lipid dioleoylphosphatidylethanolamine (DOPE). The neutral component mediates the intracellular release.
- DOTMA cationic lipid N-[1-(2,3 dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride
- DOPE neutral lipid dioleoylphosphatidylethanolamine
- Another group of delivery systems are polymeric nanoparticles.
- Polycations such like diethylaminoethylaminoethyl (DEAE)-dextran, which are well known as DNA transfection reagent can be combined with butylcyanoacrylate (PBCA) and hexylcyanoacrylate (PHCA) to formulate cationic nanoparticles that can deliver a molecule or a compound as defined herein, preferably an oligonucleotide across cell membranes into cells.
- PBCA butylcyanoacrylate
- PHCA hexylcyanoacrylate
- the cationic peptide protamine offers an alternative approach to formulate a compound as defined herein, preferably an oligonucleotide as colloids.
- This colloidal nanoparticle system can form so called proticles, which can be prepared by a simple self-assembly process to package and mediate intracellular release of a compound as defined herein, preferably an oligonucleotide.
- the skilled person may select and adapt any of the above or other commercially available alternative excipients and delivery systems to package and deliver a compound as defined herein, preferably an oligonucleotide for use in the current invention to deliver said compound for the treatment of Duchenne Muscular Dystrophy in humans.
- a compound as defined herein preferably an oligonucleotide could be covalently or non-covalently linked to a targeting ligand specifically designed to facilitate the uptake in to the cell, cytoplasm and/or its nucleus.
- a targeting ligand specifically designed to facilitate the uptake in to the cell, cytoplasm and/or its nucleus.
- ligand could comprise (i) a compound (including but not limited to peptide(-like) structures) recognising cell, tissue or organ specific elements facilitating cellular uptake and/or (ii) a chemical compound able to facilitate the uptake in to cells and/or the intracellular release of an a compound as defined herein, preferably an oligonucleotide from vesicles, e.g. endosomes or lysosomes.
- a compound as defined herein, preferably an oligonucleotide are formulated in a medicament which is provided with at least an excipient and/or a targeting ligand for delivery and/or a delivery device of said compound to a cell and/or enhancing its intracellular delivery.
- the invention also encompasses a pharmaceutically acceptable composition comprising a compound as defined herein, preferably an oligonucleotide and further comprising at least one excipient and/or a targeting ligand for delivery and/or a delivery device of said compound to a cell and/or enhancing its intracellular delivery.
- a molecule or compound or oligonucleotide may not be formulated in one single composition or preparation. Depending on their identity, the skilled person will know which type of formulation is the most appropriate for each compound.
- an in vitro concentration of a molecule or an oligonucleotide as defined herein which is ranged between 0.1 nM and 1 ⁇ M is used. More preferably, the concentration used is ranged between 0.3 to 400 nM, even more preferably between 1 to 200 nM.
- molecule or an oligonucleotide as defined herein may be used at a dose which is ranged between 0.1 and 20 mg/kg, preferably 0.5 and 10 mg/kg. If several molecules or oligonucleotides are used, these concentrations may refer to the total concentration of oligonucleotides or the concentration of each oligonucleotide added.
- oligonucleotide(s) as given above are preferred concentrations for in vitro or ex vivo uses.
- concentration of oligonucleotide(s) used may further vary and may need to be optimised any further.
- a compound preferably an oligonucleotide and an adjunct compound to be used in the invention to prevent, treat DMD are synthetically produced and administered directly to a cell, a tissue, an organ and/or patients in formulated form in a pharmaceutically acceptable composition or preparation.
- the delivery of a pharmaceutical composition to the subject is preferably carried out by one or more parenteral injections, e.g. intravenous and/or subcutaneous and/or intramuscular and/or intrathecal and/or intraventricular administrations, preferably injections, at one or at multiple sites in the human body.
- the invention provides the use of an antisense oligonucleotide or molecule according to the invention, and/or a viral-based vector that expresses one or more antisense sequences according to the invention and/or a pharmaceutical composition, for inducing and/or promoting splicing of the DMD pre-mRNA.
- the splicing is preferably modulated in a human myogenic cell or a muscle cell in vitro. More preferred is that splicing is modulated in human a myogenic cell or muscle cell in vivo.
- the invention further relates to the use of the molecule as defined herein and/or the vector as defined herein and/or or the pharmaceutical composition as defined herein for inducing and/or promoting splicing of the DMD pre-mRNA or for the preparation of a medicament for the treatment of a DMD patient.
- the verb “to comprise” and its conjugations is used in its non-limiting sense to mean that items following the word are included, but items not specifically mentioned are not excluded.
- the verb “to consist” may be replaced by “to consist essentially of” meaning that a molecule or a viral-based vector or a composition as defined herein may comprise additional component(s) than the ones specifically identified, said additional component(s) not altering the unique characteristic of the invention.
- reference to an element by the indefinite article “a” or “an” does not exclude the possibility that more than one of the element is present, unless the context clearly requires that there be one and only one of the elements.
- the indefinite article “a” or “an” thus usually means “at least one”.
- FIG. 1 In human control myotubes, a series of AONs (PS220 to PS225; SEQ ID NO: 3 to 8), all binding to a continuous stretch of at least 21 nucleotides within a specific sequence of exon 45 (i.e. SEQ ID NO:2), were tested at two different concentrations (200 and 500 nM). All six AONs were effective in inducing specific exon 45 skipping, as confirmed by sequence analysis (not shown). PS220 (SEQ ID NO:3) however, reproducibly induced highest levels of exon 45 skipping (see FIG. 2 ). (NT: non-treated cells, M: size marker).
- FIG. 2 In human control myotubes, 25-mer PS220 (SEQ ID NO: 3) was tested at increasing concentration. Levels of exon 45 skipping of up to 75% (at 400 nM) were observed reproducibly, as assessed by Agilent LabChip Analysis.
- FIG. 3 In human control myotubes, the efficiencies of a “short” 17-mer AON45-5 (SEQ ID NO:68) and its overlapping “long” 25-mer counterpart PS220 were directly compared at 200 nM and 500 nM. PS220 was markedly more efficient at both concentrations: 63% when compared to 3% obtained with 45-5. (NT: non-treated cells, M: size marker).
- AON design was based on (partly) overlapping open secondary structures of the target exon RNA as predicted by the m-fold program (Zuker,M. (2003) Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res., 31, 3406-3415), and on (partly) overlapping putative SR-protein binding sites as predicted by numerous software programs such as ESEfinder (Cartegni,L. et al.(2003) ESEfinder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res, 31, 3568-71; Smith,P. J. et al. (2006) An increased specificity score matrix for the prediction of SF2/ASF-specific exonic splicing enhancers.
- Hum.Mol.Genet. 15, 2490-2508 that predicts binding sites for the four most abundant SR proteins (SF2/ASF, SC35, SRp40 and SRp55).
- AONs were synthesized by Prosensa Therapeutics B. V. (Leiden, Netherlands), and contain 2′-O-methyl RNA and full-length phosphorothioate (PS) backbones.
- PS220 (SEQ ID NO: 3) reproducibly induced highest levels of exon 45 skipping, when compared to PS221-PS225 ( FIG. 1 ). High levels of exon 45 skipping of up to 75% were already obtained at 400 nM PS220 ( FIG. 2 ). In a direct comparison, PS220 (a 25-mer) was reproducibly more efficient in inducing exon 45 skipping than its shorter 17-mer counterpart AON 45-5 (SEQ ID NO: 68; previously published as h45AON5 (Aartsma-Rus et al.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Marine Sciences & Fisheries (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Obesity (AREA)
Abstract
Description
- The invention relates to the field of genetics, more specifically human genetics. The invention in particular relates to the modulation of splicing of the human Duchenne Muscular Dystrophy pre-mRNA.
- Myopathies are disorders that result in functional impairment of muscles. Muscular dystrophy (MD) refers to genetic diseases that are characterized by progressive weakness and degeneration of skeletal muscles. Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are the most common childhood forms of muscular dystrophy. They are recessive disorders and because the gene responsible for DMD and BMD resides on the X-chromosome, mutations mainly affect males with an incidence of about 1 in 3500 boys.
- DMD and BMD are caused by genetic defects in the DMD gene encoding dystrophin, a muscle protein that is required for interactions between the cytoskeleton and the extracellular matrix to maintain muscle fiber stability during contraction. DMD is a severe, lethal neuromuscular disorder resulting in a dependency on wheelchair support before the age of 12 and DMD patients often die before the age of thirty due to respiratory- or heart failure. In contrast, BMD patients often remain ambulatory until later in life, and have near normal life expectancies. DMD mutations in the DMD gene are mainly characterized by frame shifting insertions or deletions or nonsense point mutations, resulting in the absence of functional dystrophin. BMD mutations in general keep the reading frame intact, allowing synthesis of a partly functional dystrophin. During the last decade, specific modification of splicing in order to restore the disrupted reading frame of the DMD transcript has emerged as a promising therapy for Duchenne muscular dystrophy (DMD) (van Ommen, van Deutekom, Aartsma-Rus, Curr Opin Mol Ther. 2008;10(2)140-9, Yokota, Duddy, Partidge, Acta Myol. 2007;26(3)179-84, van Deutekom et al., N Engl J Med. 2007;357(26)2677-86).
- Using antisense oligonucleotides (AONs) interfering with splicing signals the skipping of specific exons can be induced in the DMD pre-mRNA, thus restoring the open reading frame and converting the severe DMD into a milder BMD phenotype (van Deutekom et al. Hum Mol Genet. 2001; 10: 1547-54; Aartsma-Rus et al., Hum Mol Genet 2003; 12(8)907-14.). In vivo proof-of-concept was first obtained in the mdx mouse model, which is dystrophin-deficient due to a nonsense mutation in exon 23. Intramuscular and intravenous injections of AONs targeting the mutated exon 23 restored dystrophin expression for at least three months (Lu et al. Nat Med. 2003; 8: 1009-14; Lu et al., Proc Natl Acad Sci U S A. 2005;102(1)198-203). This was accompanied by restoration of dystrophin-associated proteins at the fiber membrane as well as functional improvement of the treated muscle. In vivo skipping of human exons has also been achieved in the hDMD mouse model, which contains a complete copy of the human DMD gene integrated in chromosome 5 of the mouse (Bremmer-Bout et al. Molecular Therapy. 2004; 10: 232-40; 't Hoen et al. J Biol Chem. 2008; 283: 5899-907).
- As the majority of DMD patients have deletions that cluster in hotspot regions, the skipping of a small number of exons is applicable to relatively large numbers of patients. The actual applicability of exon skipping can be determined for deletions, duplications and point mutations reported in DMD mutation databases such as the Leiden DMD mutation database available at www.dmd.nl. Therapeutic skipping of
exon 45 of the DMD pre-mRNA would restore the open reading frame of DMD patients having deletions including but not limited to exons 12-44, 18-44, 44, 46, 46-47, 46-48, 46-49, 46-51, 46-53, 46-55, 46-59, 46-60 of the DMD pre-mRNA, occurring in a total of 16% of all DMD patients with a deletion (Aartsma-Rus and van Deutekom, 2007, Antisense Elements (Genetics) Research Focus, 2007 Nova Science Publishers, Inc). Furthermore, for some DMD patients the simultaneous skipping of one of more exons in addition toexon 45, such as exons 51 or 53 is required to restore the correct reading frame. None-limiting examples include patients with a deletion of exons 46-50 requiring the co-skipping ofexons 45 and 51, or with a deletion of exons 46-52 requiring the co-skipping ofexons 45 and 53. - Recently, a first-in-man study was successfully completed where an AON inducing the skipping of exon 51 was injected into a small area of the tibialis anterior muscle of four DMD patients. Novel dystrophin expression was observed in the majority of muscle fibers in all four patients treated, and the AON was safe and well tolerated (van Deutekom et al. N Engl J Med. 2007; 357: 2677-86).
- Most AONs studied contain up to 20 nucleotides, and it has been argued that this relatively short size improves the tissue distribution and/or cell penetration of an AON. However, such short AONs will result in a limited specificity due to an increased risk for the presence of identical sequences elsewhere in the genome, and a limited target binding or target affinity due to a low free energy of the AON-target complex. Therefore the inventors decided to design new and optionally improved oligonucleotides that would not exhibit all of these drawbacks.
- Method
- In a first aspect, the invention provides a method for inducing and/or promoting skipping of
exon 45 of DMD pre-mRNA in a patient, preferably in an isolated cell of said patient, the method comprising providing said cell and/or said patient with a molecule that binds to a continuous stretch of at least 21 nucleotides within said exon. - Accordingly, a method is herewith provided for inducing and/or promoting skipping of
exon 45 of DMD pre-mRNA, preferably in an isolated cell of a patient, the method comprising providing said cell and/or said patient with a molecule that binds to a continuous stretch of at least 21 nucleotides within said exon. - It is to be understood that said method encompasses an in vitro, in vivo or ex vivo method.
- As defined herein a DMD pre-mRNA preferably means the pre-mRNA of a DMD gene of a DMD or BMD patient. The DMD gene or protein corresponds to the dystrophin gene or protein.
- A patient is preferably intended to mean a patient having DMD or BMD as later defined herein or a patient susceptible to develop DMD or BMD due to his or her genetic background.
- Exon skipping refers to the induction in a cell of a mature mRNA that does not contain a particular exon that is normally present therein. Exon skipping is achieved by providing a cell expressing the pre-mRNA of said mRNA with a molecule capable of interfering with sequences such as, for example, the splice donor or splice acceptor sequence that are both required for allowing the enzymatic process of splicing, or a molecule that is capable of interfering with an exon inclusion signal required for recognition of a stretch of nucleotides as an exon to be included in the mRNA. The term pre-mRNA refers to a non-processed or partly processed precursor mRNA that is synthesized from a DNA template in the cell nucleus by transcription.
- Within the context of the invention inducing anchor promoting skipping of an exon as indicated herein means that at least 1%, 10%, 20%, 30%, 40%,50%, 60%, 70%, 80%, 90% or more of the DMD mRNA in one or more (muscle) cells of a treated patient will not contain said exon. This is preferably assessed by PCR as described in the examples.
- Preferably, a method of the invention by inducing or promoting skipping of
exon 45 of the DMD pre-mRNA in one or more cells of a patient provides said patient with a functional dystrophin protein and/or decreases the production of an aberrant dystrophin protein in said patient. Therefore a preferred method is a method, wherein a patient or a cell of said patient is provided with a functional dystrophin protein and/or wherein the production of an aberrant dystrophin protein in said patient or in a cell of said patient is decreased - Decreasing the production of an aberrant dystrophin may be assessed at the mRNA level and preferably means that 99%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5% or less of the initial amount of aberrant dystrophin mRNA, is still detectable by RT PCR. An aberrant dystrophin mRNA or protein is also referred to herein as a non-functional dystrophin mRNA or protein. A non functional dystrophin protein is preferably a dystrophin protein which is not able to bind actin and/or members of the DGC protein complex. A non-functional dystrophin protein or dystrophin mRNA does typically not have, or does not encode a dystrophin protein with an intact C-terminus of the protein.
- Increasing the production of a functional dystrophin in said patient or in a cell of said patient may be assessed at the mRNA level (by RT-PCR analysis) and preferably means that a detectable amount of a functional dystrophin mRNA is detectable by RT PCR. In another embodiment, 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more of the detectable dystrophin mRNA is a functional dystrophin mRNA. Increasing the production of a functional dystrophin in said patient or in a cell of said patient may be assessed at the protein level (by immuno fluorescence and western blot analyses) and preferably means that a detectable amount of a functional dystrophin protein is detectable by immunofluorescence or western blot analysis. In another embodiment, 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more of the detectable dystrophin protein is a functional dystrophin protein.
- As defined herein, a functional dystrophin is preferably a wild type dystrophin corresponding to a protein having the amino acid sequence as identified in SEQ ID NO: 1. A functional dystrophin is preferably a dystrophin, which has an actin binding domain in its N terminal part (first 240 amino acids at the N terminus), a cystein-rich domain (amino acid 3361 till 3685) and a C terminal domain (last 325 amino acids at the C terminus) each of these domains being present in a wild type dystrophin as known to the skilled person. The amino acids indicated herein correspond to amino acids of the wild type dystrophin being represented by SEQ ID NO:l. In other words, a functional dystrophin is a dystrophin which exhibits at least to some extent an activity of a wild type dystrophin. “At least to some extent” preferably means at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 100% of a corresponding activity of a wild type functional dystrophin. In this context, an activity of a functional dystrophin is preferably binding to actin and to the dystrophin-associated glycoprotein complex (DGC) (Aartsma-Rus A et al, (2006), Entries in the leiden Duchenne Muscular Dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule, Muscle Nerve, 34: 135-144). Binding of dystrophin to actin and to the DGC complex may be visualized by either co-immunoprecipitation using total protein extracts or immunofluorescence analysis of cross-sections, from a muscle biopsy, as known to the skilled person.
- Individuals or patients suffering from Duchenne muscular dystrophy typically have a mutation in the DMD gene that prevent synthesis of the complete dystrophin protein, i.e of a premature stop prevents the synthesis of the C-terminus. In Becker muscular dystrophy the DMD gene also comprises a mutation compared to the wild type gene but the mutation does typically not induce a premature stop and the C-terminus is typically synthesized. As a result a functional dystrophin protein is synthesized that has at least the same activity in kind as the wild type protein, not although not necessarily the same amount of activity. The genome of a BMD individual typically encodes a dystrophin protein comprising the N terminal part (first 240 amino acids at the N terminus), a cystein-rich domain (amino acid 3361 till 3685) and a C terminal domain (last 325 amino acids at the C terminus) but its central rod shaped domain may be shorter than the one of a wild type dystrophin (Aartsma-Rus A et al, (2006), Entries in the leiden Duchenne Muscular Dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule, Muscle Nerve, 34: 135-144). Exon—skipping for the treatment of DMD is typically directed to overcome a premature stop in the pre-mRNA by skipping an exon in the rod-shaped domain to correct the reading frame and allow synthesis of the remainder of the dystrophin protein including the C-terminus, albeit that the protein is somewhat smaller as a result of a smaller rod domain. In a preferred embodiment, an individual having DMD and being treated by a method as defined herein will be provided a dystrophin which exhibits at least to some extent an activity of a wild type dystrophin. More preferably, if said individual is a Duchenne patient or is suspected to be a Duchenne patient, a functional dystrophin is a dystrophin of an individual having BMD: typically said dystrophin is able to interact with both actin and the DGC, but its central rod shaped domain may be shorter than the one of a wild type dystrophin (Aartsma-Rus A et al, (2006), Entries in the leiden Duchenne Muscular Dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule, Muscle Nerve, 34: 135-144). The central rod-shaped domain of wild type dystrophin comprises 24 spectrin-like repeats (Aartsma-Rus A et al, (2006), Entries in the leiden Duchenne Muscular Dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule, Muscle Nerve, 34: 135-144). For example, a central rod-shaped domain of a dystrophin as provided herein may comprise 5 to 23, 10 to 22 or 12 to 18 spectrin-like repeats as long as it can bind to actin and to DGC.
- A method of the invention may alleviate one or more characteristics of a muscle cell from a DMD patient comprising deletions including but not limited to exons 12-44, 18-44, 44, 46, 46-47, 46-48, 46-49, 46-51, 46-53, 46-55, 46-59, 46-60 of the DMD pre-mRNA of said patient (Aartsma-Rus and van Deutekom, 2007, Antisense Elements (Genetics) Research Focus, 2007 Nova Science Publishers, Inc) as well as from DMD patients requiring the simultaneous skipping of one of more exons in addition to
exon 45 including but not limited to patients with a deletion of exons 46-50 requiring the co-skipping ofexons 45 and 51, or with a deletion of exons 46-52 requiring the co-skipping ofexons 45 and 53. - In a preferred method, one or more symptom(s) or characteristic(s) of a myogenic cell or muscle cell from a DMD patient is/are alleviated. Such symptoms or characteristics may be assessed at the cellular, tissue level or on the patient self.
- An alleviation of one or more symptoms or characteristics may be assessed by any of the following assays on a myogenic cell or muscle cell from a patient: reduced calcium uptake by muscle cells, decreased collagen synthesis, altered morphology, altered lipid biosynthesis, decreased oxidative stress, and/or improved muscle fiber function, integrity, and/or survival. These parameters are usually assessed using immunofluorescence and/or histochemical analyses of cross sections of muscle biopsies.
- The improvement of muscle fiber function, integrity and/or survival may also be assessed using at least one of the following assays: a detectable decrease of creatine kinase in blood, a detectable decrease of necrosis of muscle fibers in a biopsy cross-section of a muscle suspected to be dystrophic, and/or a detectable increase of the homogeneity of the diameter of muscle fibers in a biopsy cross-section of a muscle suspected to be dystrophic. Each of these assays is known to the skilled person.
- Creatine kinase may be detected in blood as described in Hodgetts et al (Hodgetts S., et al, (2006), Neuromuscular Disorders, 16: 591-602.2006). A detectable decrease in creatine kinase may mean a decrease of 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more compared to the concentration of creatine kinase in a same DMD patient before treatment.
- A detectable decrease of necrosis of muscle fibers is preferably assessed in a muscle biopsy, more preferably as described in Hodgetts et al (Hodgetts S., et al, (2006), Neuromuscular Disorders, 16: 591-602.2006) using biopsy cross-sections. A detectable decrease of necrosis may be a decrease of 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more of the area wherein necrosis has been identified using biopsy cross-sections. The decrease is measured by comparison to the necrosis as assessed in a same DMD patient before treatment.
- A detectable increase of the homogeneity of the diameter of muscle fibers is preferably assessed in a muscle biopsy cross-section, more preferably as described in Hodgetts et al (Hodgetts S., et al, (2006), Neuromuscular Disorders, 16: 591-602.2006). The increase is measured by comparison to the homogeneity of the diameter of muscle fibers in a muscle biopsy cross-section of a same DMD patient before treatment.
- An alleviation of one or more symptoms or characteristics may be assessed by any of the following assays on the patient self: prolongation of time to loss of walking, improvement of muscle strength, improvement of the ability to lift weight, improvement of the time taken to rise from the floor, improvement in the nine-meter walking time, improvement in the time taken for four-stairs climbing, improvement of the leg function grade, improvement of the pulmonary function, improvement of cardiac function, improvement of the quality of life. Each of these assays is known to the skilled person. As an example, the publication of Manzur at al (Manzur A Y et al, (2008), Glucocorticoid corticosteroids for Duchenne muscular dystrophy (review), Wiley publishers, The Cochrane collaboration.) gives an extensive explanation of each of these assays. For each of these assays, as soon as a detectable improvement or prolongation of a parameter measured in an assay has been found, it will preferably mean that one or more symptoms of Duchenne Muscular Dystrophy has been alleviated in an individual using a method of the invention. Detectable improvement or prolongation is preferably a statistically significant improvement or prolongation as described in Hodgetts et al (Hodgetts S., et al, (2006), Neuromuscular Disorders, 16: 591-602.2006). Alternatively, the alleviation of one or more symptom(s) of Duchenne Muscular Dystrophy may be assessed by measuring an improvement of a muscle fiber function, integrity and/or survival as later defined herein.
- A treatment in a method according to the invention may have a duration of at least one week, at least one month, at least several months, at least one year, at least 2, 3, 4, 5, 6 years or more. The frequency of administration of an oligonucleotide, composition, compound of the invention may depend on several parameters such as the age of the patient, the type of mutation, the number of molecules (dose), the formulation of said molecule. The frequency may be ranged between at least once in a two weeks, or three weeks or four weeks or five weeks or a longer time period. Each molecule or oligonucleotide or equivalent thereof as defined herein for use according to the invention may be suitable for direct administration to a cell, tissue and/or an organ in vivo of individuals affected by or at risk of developing DMD and may be administered directly in vivo, ex vivo or in vitro. An oligonucleotide as used herein may be suitable for administration to a cell, tissue and/or an organ in vivo of individuals affected by or at risk of developing DMD, and may be administered in vivo, ex vivo or in vitro. Said oligonucleotide may be directly or indirectly administrated to a cell, tissue and/or an organ in vivo of an individual affected by or at risk of developing DMD, and may be administered directly or indirectly in vivo, ex vivo or in vitro. As Duchenne muscular dystrophy has a pronounced phenotype in muscle cells, it is preferred that said cells are muscle cells, it is further preferred that said tissue is a muscular tissue and/or it is further preferred that said organ comprises or consists of a muscular tissue. A preferred organ is the heart. Preferably said cells comprise a gene encoding a mutant dystrophin protein. Preferably said cells are cells of an individual suffering from DMD.
- A molecule or oligonucleotide or equivalent thereof can be delivered as is to a cell. When administering said molecule, oligonucleotide or equivalent thereof to an individual, it is preferred that it is dissolved in a solution that is compatible with the delivery method. For intravenous, subcutaneous, intramuscular, intrathecal and/or intraventricular administration it is preferred that the solution is a physiological salt solution. Particularly preferred for a method of the invention is the use of an excipient that will further enhance delivery of said molecule, oligonucleotide or functional equivalent thereof as defined herein, to a cell and into a cell, preferably a muscle cell. Preferred excipient are defined in the section entitled “pharmaceutical composition”. In vitro, we obtained very good results using polyethylenimine (PEI, ExGen500, MBI Fermentas) as shown in the example.
- In a preferred method of the invention, an additional molecule is used which is able to induce and/or promote skipping of a distinct exon of the DMD pre-mRNA of a patient. Preferably, the second exon is selected from:
exon exon 45 and one oligonucleotide for exon 51 was added to a cell transcribing the DMD gene. Such a set-up resulted in mRNA being produced that did not containexons 45 to 51. Apparently, the structure of the pre-mRNA in the presence of the mentioned oligonucleotides was such that the splicing machinery was stimulated to connectexons 44 and 52 to each other. - It is possible to specifically promote the skipping of also the intervening exons by providing a linkage between the two complementary oligonucleotides. Hence, in one embodiment stretches of nucleotides complementary to at least two dystrophin exons are separated by a linking moiety. The at least two stretches of nucleotides are thus linked in this embodiment so as to form a single molecule.
- In case, more than one compounds are used in a method of the invention, said compounds can be administered to an individual in any order. In one embodiment, said compounds are administered simultaneously (meaning that said compounds are administered within 10 hours, preferably within one hour). This is however not necessary. In another embodiment, said compounds are administered sequentially.
- Molecule
- In a second aspect, there is provided a molecule for use in a method as described in the previous section entitled “Method”. This molecule preferably comprises or consists of an oligonucleotide, Said oligonucleotide is preferably an antisense oligonucleotide (AON) or antisense oligoribonucleotide.
- It was found by the present investigators that especially
exon 45 is specifically skipped at a high frequency using a molecule that binds to a continuous stretch of at least 21 nucleotides within said exon. Although this effect can be associated with a higher binding affinity of said molecule, compared to a molecule that binds to a continuous stretch of less than 21 nucleotides, there could be other intracellular parameters involved that favor thermodynamic, kinetic, or structural characteristics of the hybrid duplex. In a preferred embodiment, a molecule that binds to a continuous stretch of at least 21, 25, 30, 35, 40, 45, 50 nucleotides within said exon is used. - In a preferred embodiment, a molecule or an oligonucleotide of the invention which comprises a sequence that is complementary to a part of
exon 45 of DMD pre-mRNA is such that the complementary part is at least 50% of the length of the oligonucleotide of the invention, more preferably at least 60%, even more preferably at least 70%, even more preferably at least 80%, even more preferably at least 90% or even more preferably at least 95%, or even more preferably 98% and most preferably up to 100%. “A part ofexon 45” preferably means a stretch of at least 21 nucleotides. In a most preferred embodiment, an oligonucleotide of the invention consists of a sequence that is complementary to part ofexon 45 dystrophin pre-mRNA as defined herein. Alternatively, an oligonucleotide may comprise a sequence that is complementary to part ofexon 45 dystrophin pre-mRNA as defined herein and additional flanking sequences. In a more preferred embodiment, the length of said complementary part of said oligonucleotide is of at least 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 nucleotides. Several types of flanking sequences may be used. Preferably, additional flanking sequences are used to modify the binding of a protein to said molecule or oligonucleotide, or to modify a thermodynamic property of the oligonucleotide, more preferably to modify target RNA binding affinity. In another preferred embodiment, additional flanking sequences are complementary to sequences of the DMD pre-mRNA which are not present inexon 45. Such flanking sequences are preferably complementary to sequences comprising or consisting of the splice site acceptor or donor consensus sequences ofexon 45. In a preferred embodiment, such flanking sequences are complementary to sequences comprising or consisting of sequences of an intron of the DMD pre-mRNA which is adjacent toexon 45; i.e.intron - A continuous stretch of at least 21, 25, 30, 35, 40, 45, 50 nucleotides within
exon 45 is preferably selected from the sequence: -
(SEQ ID NO 2) 5′-CCAGGAUGGCAUUGGGCAGCGGCAAACUGUUGUCAGA ACAUUGAAUGCAACUGGGGAAGAAAUAAUUCAGCAAUC-3′. - It was found that a molecule that binds to a nucleotide sequence comprising or consisting of a continuous stretch of at least 21, 25, 30, 35, 40, 45, 50 nucleotides of SEQ ID NO. 2 results in highly efficient skipping of
exon 45 in a cell provided with this molecule. Molecules that bind to a nucleotide sequence comprising a continuous stretch of less than 21 nucleotides of SEQ ID NO:2 were found to induce exon skipping in a less efficient way than the molecules of the invention. Therefore, in a preferred embodiment, a method is provided wherein a molecule binds to a continuous stretch of at least 21, 25, 30, 35 nucleotides within SEQ ID NO:2. Contrary to what was generally thought, the inventors surprisingly found that a higher specificity and efficiency of exon skipping may be reached using an oligonucleotides having a length of at least 21 nucleotides. None of the indicated sequences is derived from conserved parts of splice-junction sites. Therefore, said molecule is not likely to mediate differential splicing of other exons from the DMD pre-mRNA or exons from other genes. - In one embodiment, a molecule of the invention capable of interfering with the inclusion of
exon 45 of the DMD pre-mRNA is a compound molecule that binds to the specified sequence, or a protein such as an RNA-binding protein or a non-natural zinc-finger protein that has been modified to be able to bind to the indicated nucleotide sequence on a RNA molecule. Methods for screening compound molecules that bind specific nucleotide sequences are for example disclosed in PCT/NL01/00697 and US patent 6875736, which are herein enclosed by reference. Methods for designing RNA-binding Zinc-finger proteins that bind specific nucleotide sequences are disclosed by Friesen and Darby, Nature Structural Biology 5: 543-546 (1998) which is herein enclosed by reference. - In a further embodiment, a molecule of the invention capable of interfering with the inclusion of
exon 45 of the DMD pre-mRNA comprises an antisense oligonucleotide that is complementary to and can base-pair with the coding strand of the pre-mRNA of the DMD gene. Said antisense oligonucleotide preferably contains a RNA residue, a DNA residue, and/or a nucleotide analogue or equivalent, as will be further detailed herein below. - A preferred molecule of the invention comprises a nucleotide-based or nucleotide or an antisense oligonucleotide sequence of between 21 and 50 nucleotides or bases, more preferred between 21 and 40 nucleotides, more preferred between 21 and 30 nucleotides, such as 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, 25 nucleotides, 26 nucleotides, 27 nucleotides, 28 nucleotides, 29 nucleotides, 30 nucleotides, 31 nucleotides, 32 nucleotides, 33 nucleotides, 34 nucleotides, 35 nucleotides, 36 nucleotides, 37 nucleotides, 38 nucleotides, 39 nucleotides, 40 nucleotides, 41 nucleotides, 42 nucleotides, 43 nucleotides, 44 nucleotides, 45 nucleotides, 46 nucleotides, 47 nucleotides, 48 nucleotides, 49 nucleotides or 50 nucleotides.
- A most preferred molecule of the invention comprises a nucleotide-based sequence of 25 nucleotides.
- In a preferred embodiment, a molecule of the invention binds to a continuous stretch of or is complementary to or is antisense to at least a continuous stretch of at least 21 nucleotides within the nucleotide sequence SEQ ID NO:2.
- In a certain embodiment, the invention provides a molecule comprising or consisting of an antisense nucleotide sequence selected from the antisense nucleotide sequences as depicted in Table 1, except SEQ ID NO:68. A molecule of the invention that is antisense to the sequence of SEQ ID NO 2, which is present in exon 45 of the DMD gene preferably comprises or consists of the antisense nucleotide sequence of SEQ ID NO 3; SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO 7, SEQ ID NO 8, SEQ ID NO 9, SEQ ID NO 10, SEQ ID NO 11, SEQ ID NO 12, SEQ ID NO 13, SEQ ID NO 14, SEQ ID NO 15, SEQ ID NO 16, SEQ ID NO 17, SEQ ID NO 18, SEQ ID NO 19, SEQ ID NO 20, SEQ ID NO 21, SEQ ID NO 22, SEQ ID NO 23, SEQ ID NO 24, SEQ ID NO 25, SEQ ID NO 26, SEQ ID NO 27, SEQ ID NO 28, SEQ ID NO 29, SEQ ID NO 30, SEQ ID NO 31, SEQ ID NO 32, SEQ ID NO 33, SEQ ID NO 34, SEQ ID NO 35, SEQ ID NO 36, SEQ ID NO 37, SEQ ID NO 38, SEQ ID NO 39, SEQ ID NO 40, SEQ ID NO 41, SEQ ID NO 42, SEQ ID NO 43, SEQ ID NO 44, SEQ ID NO 45, SEQ ID NO 46, SEQ ID NO 47, SEQ ID NO 48, SEQ ID NO 49, SEQ ID NO 50, SEQ ID NO 51, SEQ ID NO 52, SEQ ID NO 53, SEQ ID NO 54, SEQ ID NO 55, SEQ ID NO 56, SEQ ID NO 57, SEQ ID NO 58, SEQ ID NO 59, SEQ ID NO 60, SEQ ID NO 61, SEQ ID NO 62, SEQ ID NO 63, SEQ ID NO 64, SEQ ID NO 65, SEQ ID NO 66 and/or SEQ ID NO:67.
- In a more preferred embodiment, the invention provides a molecule comprising or consisting of the antisense nucleotide sequence of
SEQ ID NO 3; SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO 7 and/or SEQ ID NO 8. - In a most preferred embodiment, the invention provides a molecule comprising or consisting of the antisense nucleotide sequence of
SEQ ID NO 3. It was found that this molecule is very efficient in modulating splicing ofexon 45 of the DMD pre-mRNA in a muscle cell. - A nucleotide sequence of a molecule of the invention may contain a RNA residue, a DNA residue, a nucleotide analogue or equivalent as will be further detailed herein below. In addition, a molecule of the invention may encompass a functional equivalent of a molecule of the invention as defined herein.
- It is preferred that a molecule of the invention comprises a or at least one residue that is modified to increase nuclease resistance, and/or to increase the affinity of the antisense nucleotide for the target sequence. Therefore, in a preferred embodiment, an antisense nucleotide sequence comprises a or at least one nucleotide analogue or equivalent, wherein a nucleotide analogue or equivalent is defined as a residue having a modified base, and/or a modified backbone, and/or a non-natural internucleoside linkage, or a combination of these modifications.
- In a preferred embodiment, a nucleotide analogue or equivalent comprises a modified backbone. Examples of such backbones are provided by morpholino backbones, carbamate backbones, siloxane backbones, sulfide, sulfoxide and sulfone backbones, formacetyl and thioformacetyl backbones, methyleneformacetyl backbones, riboacetyl backbones, alkene containing backbones, sulfamate, sulfonate and sulfonamide backbones, methyleneimino and methylenehydrazino backbones, and amide backbones. Phosphorodiamidate morpholino oligomers are modified backbone oligonucleotides that have previously been investigated as antisense agents. Morpholino oligonucleotides have an uncharged backbone in which the deoxyribose sugar of DNA is replaced by a six membered ring and the phosphodiester linkage is replaced by a phosphorodiamidate linkage. Morpholino oligonucleotides are resistant to enzymatic degradation and appear to function as antisense agents by arresting translation or interfering with pre-mRNA splicing rather than by activating RNase H. Morpholino oligonucleotides have been successfully delivered to tissue culture cells by methods that physically disrupt the cell membrane, and one study comparing several of these methods found that scrape loading was the most efficient method of delivery; however, because the morpholino backbone is uncharged, cationic lipids are not effective mediators of morpholino oligonucleotide uptake in cells. A recent report demonstrated triplex formation by a morpholino oligonucleotide and, because of the non-ionic backbone, these studies showed that the morpholino oligonucleotide was capable of triplex formation in the absence of magnesium.
- It is further preferred that the linkage between a residue in a backbone does not include a phosphorus atom, such as a linkage that is formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages.
- A preferred nucleotide analogue or equivalent comprises a Peptide Nucleic Acid (PNA), having a modified polyamide backbone (Nielsen, et al. (1991) Science 254, 1497-1500). PNA-based molecules are true mimics of DNA molecules in terms of base-pair recognition. The backbone of the PNA is composed of N-(2-aminoethyl)-glycine units linked by peptide bonds, wherein the nucleobases are linked to the backbone by methylene carbonyl bonds. An alternative backbone comprises a one-carbon extended pyrrolidine PNA monomer (Govindaraju and Kumar (2005) Chem. Commun, 495-497). Since the backbone of a PNA molecule contains no charged phosphate groups, PNA-RNA hybrids are usually more stable than RNA-RNA or RNA-DNA hybrids, respectively (Egholm et al (1993) Nature 365, 566-568).
- A further preferred backbone comprises a morpholino nucleotide analog or equivalent, in which the ribose or deoxyribose sugar is replaced by a 6-membered morpholino ring. A most preferred nucleotide analog or equivalent comprises a phosphorodiamidate morpholino oligomer (PMO), in which the ribose or deoxyribose sugar is replaced by a 6-membered morpholino ring, and the anionic phosphodiester linkage between adjacent morpholino rings is replaced by a non-ionic phosphorodiamidate linkage.
- In yet a further embodiment, a nucleotide analogue or equivalent of the invention comprises a substitution of at least one of the non-bridging oxygens in the phosphodiester linkage. This modification slightly destabilizes base-pairing but adds significant resistance to nuclease degradation. A preferred nucleotide analogue or equivalent comprises phosphorothioate, chiral phosphorothioate, phosphorodithioate, phosphotriester, aminoalkylphosphotriester, H-phosphonate, methyl and other alkyl phosphonate including 3′-alkylene phosphonate, 5′-alkylene phosphonate and chiral phosphonate, phosphinate, phosphoramidate including 3′-amino phosphoramidate and aminoalkylphosphoramidate, thionophosphoramidate, thionoalkylphosphonate, thionoalkylphosphotriester, selenophosphate or boranophosphate.
- A further preferred nucleotide analogue or equivalent of the invention comprises one or more sugar moieties that are mono- or disubstituted at the 2′, 3′ and/or 5′ position such as a —OH; —F; substituted or unsubstituted, linear or branched lower (C1-C10) alkyl, alkenyl, alkynyl, alkaryl, allyl, aryl, or aralkyl, that may be interrupted by one or more heteroatoms; O—, S—, or N-alkyl; O—, S—, or N-alkenyl; O—, S-or N-alkynyl; O—, S—, or N-allyl; O-alkyl-O-alkyl, -methoxy, -aminopropoxy; aminoxy, methoxyethoxy; -dimethylaminooxyethoxy; and -dimethylaminoethoxyethoxy. The sugar moiety can be a pyranose or derivative thereof, or a deoxypyranose or derivative thereof, preferably a ribose or a derivative thereof, or deoxyribose or derivative thereof. Such preferred derivatized sugar moieties comprise Locked Nucleic Acid (LNA), in which the 2′-carbon atom is linked to the 3′ or 4′ carbon atom of the sugar ring thereby forming a bicyclic sugar moiety. A preferred LNA comprises 2′-O,4′-C-ethylene-bridged nucleic acid (Morita et al. 2001. Nucleic Acid Res Supplement No. 1: 241-242). These substitutions render the nucleotide analogue or equivalent RNase H and nuclease resistant and increase the affinity for the target RNA.
- It is understood by a skilled person that it is not necessary for all positions in an antisense oligonucleotide to be modified uniformly. In addition, more than one of the aforementioned analogues or equivalents may be incorporated in a single antisense oligonucleotide or even at a single position within an antisense oligonucleotide. In certain embodiments, an antisense oligonucleotide of the invention has at least two different types of analogues or equivalents.
- A preferred antisense oligonucleotide according to the invention comprises a 2′-O -alkyl phosphorothioate antisense oligonucleotide, such as 2′-O-methyl modified ribose (RNA), 2′-O-ethyl modified ribose, 2′-O-propyl modified ribose, and/or substituted derivatives of these modifications such as halogenated derivatives.
- A most preferred antisense oligonucleotide according to the invention comprises a 2′-O-methyl phosphorothioate ribose.
- A functional equivalent of a molecule of the invention may be defined as an oligonucleotide as defined herein wherein an activity of said functional equivalent is retained to at least some extent. Preferably, an activity of said functional equivalent is inducing
exon 45 skipping and providing a functional dystrophin protein. Said activity of said functional equivalent is therefore preferably assessed by detection ofexon 45 skipping and quantifying the amount of a functional dystrophin protein. A functional dystrophin is herein preferably defined as being a dystrophin able to bind actin and members of the DGC protein complex. The assessment of said activity of an oligonucleotide is preferably done by RT-PCR or by immunofluorescence or Western blot analysis. Said activity is preferably retained to at least some extent when it represents at least 50%, or at least 60%, or at least 70% or at least 80% or at least 90% or at least 95% or more of corresponding activity of said oligonucleotide the functional equivalent derives from. Throughout this application, when the word oligonucleotide is used it may be replaced by a functional equivalent thereof as defined herein. - It will also be understood by a skilled person that distinct antisense oligonucleotides can be combined for efficiently skipping of
exon 45 of the human DMD pre-mRNA. In a preferred embodiment, a combination of at least two antisense oligonucleotides are used in a method of the invention, such as two distinct antisense oligonucleotides, three distinct antisense oligonucleotides, four distinct antisense oligonucleotides, or five distinct antisense oligonucleotides or even more. It is also encompassed by the present invention to combine several oligonucleotides or molecules as depicted in table 1 except SEQ ID NO:68. - An antisense oligonucleotide can be linked to a moiety that enhances uptake of the antisense oligonucleotide in cells, preferably myogenic cells or muscle cells. Examples of such moieties are cholesterols, carbohydrates, vitamins, biotin, lipids, phospholipids, cell-penetrating peptides including but not limited to antennapedia, TAT, transportan and positively charged amino acids such as oligoarginine, poly-arginine, oligolysine or polylysine, antigen-binding domains such as provided by an antibody, a Fab fragment of an antibody, or a single chain antigen binding domain such as a cameloid single domain antigen-binding domain.
- A preferred antisense oligonucleotide comprises a peptide-linked PMO.
- A preferred antisense oligonucleotide comprising one or more nucleotide analogs or equivalents of the invention modulates splicing in one or more muscle cells, including heart muscle cells, upon systemic delivery. In this respect, systemic delivery of an antisense oligonucleotide comprising a specific nucleotide analog or equivalent might result in targeting a subset of muscle cells, while an antisense oligonucleotide comprising a distinct nucleotide analog or equivalent might result in targeting of a different subset of muscle cells. Therefore, in one embodiment it is preferred to use a combination of antisense oligonucleotides comprising different nucleotide analogs or equivalents for modulating skipping of
exon 45 of the human DMD pre-mRNA. - A cell can be provided with a molecule capable of interfering with essential sequences that result in highly efficient skipping of
exon 45 of the human DMD pre-mRNA by plasmid-derived antisense oligonucleotide expression or viral expression provided by viral-based vector. Such a viral-based vector comprises an expression cassette that drives expression of an antisense molecule as defined herein. Preferred virus-based vectors include adenovirus- or adeno-associated virus-based vectors. Expression is preferably driven by a polymerase III promoter, such as a U1, a U6, or a U7 RNA promoter. A muscle or myogenic cell can be provided with a plasmid for antisense oligonucleotide expression by providing the plasmid in an aqueous solution. Alternatively, a plasmid can be provided by transfection using known transfection agentia such as, for example, LipofectAMINETM 2000 (Invitrogen) or polyethyleneimine (PEI; ExGen500 (MBI Fermentas)), or derivatives thereof. - One preferred antisense oligonucleotide expression system is an adenovirus associated virus (AAV)-based vector. Single chain and double chain AAV-based vectors have been developed that can be used for prolonged expression of small antisense nucleotide sequences for highly efficient skipping of
exon 45 of the DMD pre-mRNA. - A preferred AAV-based vector comprises an expression cassette that is driven by a polymerase III-promoter (Pol III). A preferred Pol III promoter is, for example, a U1, a U6, or a U7 RNA promoter.
- The invention therefore also provides a viral-based vector, comprising a Pol III-promoter driven expression cassette for expression of one or more antisense sequences of the invention for inducing skipping of
exon 45 of the human DMD pre-mRNA. - If required, a molecule or a vector expressing an antisense oligonucleotide of the invention can be incorporated into a pharmaceutically active mixture or composition by adding a pharmaceutically acceptable carrier.
- Therefore, in a further aspect, the invention provides a composition, preferably a pharmaceutical composition comprising a molecule comprising an antisense oligonucleotide according to the invention, and/or a viral-based vector expressing the antisense sequence(s) according to the invention and a pharmaceutically acceptable carrier.
- A preferred pharmaceutical composition comprises a molecule as defined herein and/or a vector as defined herein, and a pharmaceutical acceptable carrier or excipient, optionally combined with a molecule and/or a vector which is able to modulate skipping of
exon - Preferred excipients include excipients capable of forming complexes, vesicles and/or liposomes that deliver such a molecule as defined herein, preferably an oligonucleotide complexed or trapped in a vesicle or liposome through a cell membrane. Many of these excipients are known in the art. Suitable excipients comprise polyethylenimine and derivatives, or similar cationic polymers, including polypropyleneimine or polyethylenimine copolymers (PECs) and derivatives, synthetic amphiphils, lipofectin™, DOTAP and/or viral capsid proteins that are capable of self assembly into particles that can deliver such molecule, preferably an oligonucleotide as defined herein to a cell, preferably a muscle cell. Such excipients have been shown to efficiently deliver (oligonucleotide such as antisense) nucleic acids to a wide variety of cultured cells, including muscle cells. We obtained very good results using polyethylenimine (PEI, ExGen500, MBI Fermentas) as shown in the example. Their high transfection potential is combined with an excepted low to moderate toxicity in terms of overall cell survival. The ease of structural modification can be used to allow further modifications and the analysis of their further (in vivo) nucleic acid transfer characteristics and toxicity.
- Lipofectin represents an example of a liposomal transfection agent. It consists of two lipid components, a cationic lipid N-[1-(2,3 dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA) (cp. DOTAP which is the methylsulfate salt) and a neutral lipid dioleoylphosphatidylethanolamine (DOPE). The neutral component mediates the intracellular release. Another group of delivery systems are polymeric nanoparticles.
- Polycations such like diethylaminoethylaminoethyl (DEAE)-dextran, which are well known as DNA transfection reagent can be combined with butylcyanoacrylate (PBCA) and hexylcyanoacrylate (PHCA) to formulate cationic nanoparticles that can deliver a molecule or a compound as defined herein, preferably an oligonucleotide across cell membranes into cells.
- In addition to these common nanoparticle materials, the cationic peptide protamine offers an alternative approach to formulate a compound as defined herein, preferably an oligonucleotide as colloids. This colloidal nanoparticle system can form so called proticles, which can be prepared by a simple self-assembly process to package and mediate intracellular release of a compound as defined herein, preferably an oligonucleotide. The skilled person may select and adapt any of the above or other commercially available alternative excipients and delivery systems to package and deliver a compound as defined herein, preferably an oligonucleotide for use in the current invention to deliver said compound for the treatment of Duchenne Muscular Dystrophy in humans.
- In addition, a compound as defined herein, preferably an oligonucleotide could be covalently or non-covalently linked to a targeting ligand specifically designed to facilitate the uptake in to the cell, cytoplasm and/or its nucleus. Such ligand could comprise (i) a compound (including but not limited to peptide(-like) structures) recognising cell, tissue or organ specific elements facilitating cellular uptake and/or (ii) a chemical compound able to facilitate the uptake in to cells and/or the intracellular release of an a compound as defined herein, preferably an oligonucleotide from vesicles, e.g. endosomes or lysosomes.
- Therefore, in a preferred embodiment, a compound as defined herein, preferably an oligonucleotide are formulated in a medicament which is provided with at least an excipient and/or a targeting ligand for delivery and/or a delivery device of said compound to a cell and/or enhancing its intracellular delivery. Accordingly, the invention also encompasses a pharmaceutically acceptable composition comprising a compound as defined herein, preferably an oligonucleotide and further comprising at least one excipient and/or a targeting ligand for delivery and/or a delivery device of said compound to a cell and/or enhancing its intracellular delivery.
- It is to be understood that a molecule or compound or oligonucleotide may not be formulated in one single composition or preparation. Depending on their identity, the skilled person will know which type of formulation is the most appropriate for each compound.
- In a preferred embodiment, an in vitro concentration of a molecule or an oligonucleotide as defined herein, which is ranged between 0.1 nM and 1 μM is used. More preferably, the concentration used is ranged between 0.3 to 400 nM, even more preferably between 1 to 200 nM. molecule or an oligonucleotide as defined herein may be used at a dose which is ranged between 0.1 and 20 mg/kg, preferably 0.5 and 10 mg/kg. If several molecules or oligonucleotides are used, these concentrations may refer to the total concentration of oligonucleotides or the concentration of each oligonucleotide added. The ranges of concentration of oligonucleotide(s) as given above are preferred concentrations for in vitro or ex vivo uses. The skilled person will understand that depending on the oligonucleotide(s) used, the target cell to be treated, the gene target and its expression levels, the medium used and the transfection and incubation conditions, the concentration of oligonucleotide(s) used may further vary and may need to be optimised any further.
- More preferably, a compound preferably an oligonucleotide and an adjunct compound to be used in the invention to prevent, treat DMD are synthetically produced and administered directly to a cell, a tissue, an organ and/or patients in formulated form in a pharmaceutically acceptable composition or preparation. The delivery of a pharmaceutical composition to the subject is preferably carried out by one or more parenteral injections, e.g. intravenous and/or subcutaneous and/or intramuscular and/or intrathecal and/or intraventricular administrations, preferably injections, at one or at multiple sites in the human body.
- In yet a further aspect, the invention provides the use of an antisense oligonucleotide or molecule according to the invention, and/or a viral-based vector that expresses one or more antisense sequences according to the invention and/or a pharmaceutical composition, for inducing and/or promoting splicing of the DMD pre-mRNA. The splicing is preferably modulated in a human myogenic cell or a muscle cell in vitro. More preferred is that splicing is modulated in human a myogenic cell or muscle cell in vivo.
- Accordingly, the invention further relates to the use of the molecule as defined herein and/or the vector as defined herein and/or or the pharmaceutical composition as defined herein for inducing and/or promoting splicing of the DMD pre-mRNA or for the preparation of a medicament for the treatment of a DMD patient.
- In this document and in its claims, the verb “to comprise” and its conjugations is used in its non-limiting sense to mean that items following the word are included, but items not specifically mentioned are not excluded. In addition the verb “to consist” may be replaced by “to consist essentially of” meaning that a molecule or a viral-based vector or a composition as defined herein may comprise additional component(s) than the ones specifically identified, said additional component(s) not altering the unique characteristic of the invention. In addition, reference to an element by the indefinite article “a” or “an” does not exclude the possibility that more than one of the element is present, unless the context clearly requires that there be one and only one of the elements. The indefinite article “a” or “an” thus usually means “at least one”.
- Each embodiment as identified herein may be combined together unless otherwise indicated. All patent and literature references cited in the present specification are hereby incorporated by reference in their entirety.
- The following examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.
-
FIG. 1 . In human control myotubes, a series of AONs (PS220 to PS225; SEQ ID NO: 3 to 8), all binding to a continuous stretch of at least 21 nucleotides within a specific sequence of exon 45 (i.e. SEQ ID NO:2), were tested at two different concentrations (200 and 500 nM). All six AONs were effective in inducingspecific exon 45 skipping, as confirmed by sequence analysis (not shown). PS220 (SEQ ID NO:3) however, reproducibly induced highest levels ofexon 45 skipping (seeFIG. 2 ). (NT: non-treated cells, M: size marker). -
FIG. 2 . In human control myotubes, 25-mer PS220 (SEQ ID NO: 3) was tested at increasing concentration. Levels ofexon 45 skipping of up to 75% (at 400 nM) were observed reproducibly, as assessed by Agilent LabChip Analysis. -
FIG. 3 . In human control myotubes, the efficiencies of a “short” 17-mer AON45-5 (SEQ ID NO:68) and its overlapping “long” 25-mer counterpart PS220 were directly compared at 200 nM and 500 nM. PS220 was markedly more efficient at both concentrations: 63% when compared to 3% obtained with 45-5. (NT: non-treated cells, M: size marker). - Materials and Methods
- AON design was based on (partly) overlapping open secondary structures of the target exon RNA as predicted by the m-fold program (Zuker,M. (2003) Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res., 31, 3406-3415), and on (partly) overlapping putative SR-protein binding sites as predicted by numerous software programs such as ESEfinder (Cartegni,L. et al.(2003) ESEfinder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res, 31, 3568-71; Smith,P. J. et al. (2006) An increased specificity score matrix for the prediction of SF2/ASF-specific exonic splicing enhancers. Hum.Mol.Genet., 15, 2490-2508) that predicts binding sites for the four most abundant SR proteins (SF2/ASF, SC35, SRp40 and SRp55). AONs were synthesized by Prosensa Therapeutics B. V. (Leiden, Netherlands), and contain 2′-O-methyl RNA and full-length phosphorothioate (PS) backbones.
- Tissue culturing, transfection and RT-PCR analysis Myotube cultures derived from a healthy individual (“human control”) were obtained as described previously (Aartsma-Rus et al. Hum Mol Genet 2003; 12(8): 907-14). For the screening of AONs, myotube cultures were transfected with 0 to 500 nM of each AON. The transfection reagent polyethylenimine (PEI, ExGen500 MBI Fermentas) was used according to manufacturer's instructions, with 2 μl PEI per μg AON. Exon skipping efficiencies were determined by nested RT-PCR analysis using primers in the
exons flanking exon 45. PCR fragments were isolated from agarose gels for sequence verification. For quantification, the PCR products were analyzed using the Agilent DNA 1000 LabChip Kit and the Agilent 2100 bioanalyzer (Agilent Technologies, USA). - Results
- A series of AONs targeting sequences within SEQ ID NO:2 within
exon 45 were designed and tested in normal myotube cultures, by transfection and subsequent RT-PCR and sequence analysis of isolated RNA. PS220 (SEQ ID NO: 3) reproducibly induced highest levels ofexon 45 skipping, when compared to PS221-PS225 (FIG. 1 ). High levels ofexon 45 skipping of up to 75% were already obtained at 400 nM PS220 (FIG. 2 ). In a direct comparison, PS220 (a 25-mer) was reproducibly more efficient in inducingexon 45 skipping than its shorter 17-mer counterpart AON 45-5 (SEQ ID NO: 68; previously published as h45AON5 (Aartsma-Rus et al. Am J Hum Genet 2004;74: 83-92)), at both AON concentrations of 200 nM and 500 nM and with 63% versus 3% respectively at 500 nM (FIG. 3 ). This result is probably due to the fact that the extended length of PS220, in fact completely overlapping AON 45-5, increases the free energy of the AON-target complex such that the efficiency of inducingexon 45 skipping is also increased. -
TABLE 1 AONs in exon 45 SEQ ID NO 3 UUUGCCGCUGCCCAAUGCCAUCCUG SEQ ID NO 36 GUUGCAUUCAAUGUUCUGACAACAG (PS220) SEQ ID NO 4 AUUCAAUGUUCUGACAACAGUUUGC SEQ ID NO 37 UUGCAUUCAAUGUUCUGACAACAGU (PS221) SEQ ID NO 5 CCAGUUGCAUUCAAUGUUCUGACAA SEQ ID NO 38 UGCAUUCAAUGUUCUGACAACAGUU (PS222) SEQ ID NO 6 CAGUUGCAUUCAAUGUUCUGAC SEQ ID NO 39 GCAUUCAAUGUUCUGACAACAGUUU (PS223) SEQ ID NO 7 AGUUGCAUUCAAUGUUCUGA SEQ ID NO 40 CAUUCAAUGUUCUGACAACAGUUUG (PS224) SEQ ID NO 8 GAUUGCUGAAUUAUUUCUUCC SEQ ID NO 41 AUUCAAUGUUCUGACAACAGUUUGC (PS225) SEQ ID NO 9 GAUUGCUGAAUUAUUUCUUCCCCAG SEQ ID NO 42 UCAAUGUUCUGACAACAGUUUGCCG SEQ ID NO 10 AUUGCUGAAUUAUUUCUUCCCCAGU SEQ ID NO 43 CAAUGUUCUGACAACAGUUUGCCGC SEQ ID NO 11 UUGCUGAAUUAUUUCUUCCCCAGUU SEQ ID NO 44 AAUGUUCUGACAACAGUUUGCCGCU SEQ ID NO 12 UGCUGAAUUAUUUCUUCCCCAGUUG SEQ ID NO 45 AUGUUCUGACAACAGUUUGCCGCUG SEQ ID NO 13 GCUGAAUUAUUUCUUCCCCAGUUGC SEQ ID NO 46 UGUUCUGACAACAGUUUGCCGCUGC SEQ ID NO 14 CUGAAUUAUUUCUUCCCCAGUUGCA SEQ ID NO 47 GUUCUGACAACAGUUUGCCGCUGCC SEQ ID NO 15 UGAAUUAUUUCUUCCCCAGUUGCAU SEQ ID NO 48 UUCUGACAACAGUUUGCCGCUGCCC SEQ ID NO 16 GAAUUAUUUCUUCCCCAGUUGCAUU SEQ ID NO 49 UCUGACAACAGUUUGCCGCUGCCCA SEQ ID NO 17 AAUUAUUUCUUCCCCAGUUGCAUUC SEQ ID NO 50 CUGACAACAGUUUGCCGCUGCCCAA SEQ ID NO 18 AUUAUUUCUUCCCCAGUUGCAUUCA SEQ ID NO 51 UGACAACAGUUUGCCGCUGCCCAAU SEQ ID NO 19 UUAUUUCUUCCCCAGUUGCAUUCAA SEQ ID NO 52 GACAACAGUUUGCCGCUGCCCAAUG SEQ ID NO 20 UAUUUCUUCCCCAGUUGCAUUCAAU SEQ ID NO 53 ACAACAGUUUGCCGCUGCCCAAUGC SEQ ID NO 21 AUUUCUUCCCCAGUUGCAUUCAAUG SEQ ID NO 54 CAACAGUUUGCCGCUGCCCAAUGCC SEQ ID NO 22 UUUCUUCCCCAGUUGCAUUCAAUGU SEQ ID NO 55 AACAGUUUGCCGCUGCCCAAUGCCA SEQ ID NO 23 UUCUUCCCCAGUUGCAUUCAAUGUU SEQ ID NO 56 ACAGUUUGCCGCUGCCCAAUGCCAU SEQ ID NO 24 UCUUCCCCAGUUGCAUUCAAUGUUC SEQ ID NO 57 CAGUUUGCCGCUGCCCAAUGCCAUC SEQ ID NO 25 CUUCCCCAGUUGCAUUCAAUGUUCU SEQ ID NO 58 AGUUUGCCGCUGCCCAAUGCCAUCC SEQ ID NO 26 UUCCCCAGUUGCAUUCAAUGUUCUG SEQ ID NO 59 GUUUGCCGCUGCCCAAUGCCAUCCU SEQ ID NO 27 UCCCCAGUUGCAUUCAAUGUUCUGA SEQ ID NO 60 UUUGCCGCUGCCCAAUGCCAUCCUG SEQ ID NO 28 CCCCAGUUGCAUUCAAUGUUCUGAC SEQ ID NO 61 UUGCCGCUGCCCAAUGCCAUCCUGG SEQ ID NO 29 CCCAGUUGCAUUCAAUGUUCUGACA SEQ ID NO 62 UGCCGCUGCCCAAUGCCAUCCUGGA SEQ ID NO 30 CCAGUUGCAUUCAAUGUUCUGACAA SEQ ID NO 63 GCCGCUGCCCAAUGCCAUCCUGGAG SEQ ID NO 31 CAGUUGCAUUCAAUGUUCUGACAAC SEQ ID NO 64 CCGCUGCCCAAUGCCAUCCUGGAGU SEQ ID NO 32 AGUUGCAUUCAAUGUUCUGACAACA SEQ ID NO 65 CGCUGCCCAAUGCCAUCCUGGAGUU SEQ ID NO 33 UCC UGU AGA AUA CUG GCA UC SEQ ID NO 66 UGU UUU UGA GGA UUG CUG AA SEQ ID NO 34 UGC AGA CCU CCU GCC ACC GCA SEQ ID NO 67 UGUUCUGACAACAGUUUGCCGCUGCCCAAU GAU UCA GCCAUCCUGG SEQ ID NO 35 UUGCAGACCUCCUGCCACCGCAGAUUC SEQ ID NO 68 GCCCAAUGCCAUCCUGG AGGCUUC (45-5) -
TABLE 2 AONs in exons 51, 53, 7, 44, 46, 59, and 67 DMD Gene Exon 51 SEQ ID NO 69 AGAGCAGGUACCUCCAACAUCAAGG SEQ ID NO 91 UCAAGGAAGAUGGCAUUUCUAGUUU SEQ ID NO 70 GAGCAGGUACCUCCAACAUCAAGGA SEQ ID NO 92 UCAAGGAAGAUGGCAUUUCU SEQ ID NO 71 AGCAGGUACCUCCAACAUCAAGGAA SEQ ID NO 93 CAAGGAAGAUGGCAUUUCUAGUUUG SEQ ID NO 72 GCAGGUACCUCCAACAUCAAGGAAG SEQ ID NO 94 AAGGAAGAUGGCAUUUCUAGUUUGG SEQ ID NO 73 CAGGUACCUCCAACAUCAAGGAAGA SEQ ID NO 95 AGGAAGAUGGCAUUUCUAGUUUGGA SEQ ID NO 74 AGGUACCUCCAACAUCAAGGAAGAU SEQ ID NO 96 GGAAGAUGGCAUUUCUAGUUUGGAG SEQ ID NO 75 GGUACCUCCAACAUCAAGGAAGAUG SEQ ID NO 97 GAAGAUGGCAUUUCUAGUUUGGAGA SEQ ID NO 76 GUACCUCCAACAUCAAGGAAGAUGG SEQ ID NO 98 AAGAUGGCAUUUCUAGUUUGGAGAU SEQ ID NO 77 UACCUCCAACAUCAAGGAAGAUGGC SEQ ID NO 99 AGAUGGCAUUUCUAGUUUGGAGAUG SEQ ID NO 78 ACCUCCAACAUCAAGGAAGAUGGCA SEQ ID NO 100 GAUGGCAUUUCUAGUUUGGAGAUGG SEQ ID NO 79 CCUCCAACAUCAAGGAAGAUGGCAU SEQ ID NO 101 AUGGCAUUUCUAGUUUGGAGAUGGC SEQ ID NO 80 CUCCAACAUCAAGGAAGAUGGCAUU SEQ ID NO 102 UGGCAUUUCUAGUUUGGAGAUGGCA SEQ ID NO 81 CUCCAACAUCAAGGAAGAUGGCAUUUCUAG SEQ ID NO 103 GGCAUUUCUAGUUUGGAGAUGGCAG SEQ ID NO 82 UCCAACAUCAAGGAAGAUGGCAUUU SEQ ID NO 104 GCAUUUCUAGUUUGGAGAUGGCAGU SEQ ID NO 83 CCAACAUCAAGGAAGAUGGCAUUUC SEQ ID NO 105 CAUUUCUAGUUUGGAGAUGGCAGUU SEQ ID NO 84 CAACAUCAAGGAAGAUGGCAUUUCU SEQ ID NO 106 AUUUCUAGUUUGGAGAUGGCAGUUU SEQ ID NO 85 AACAUCAAGGAAGAUGGCAUUUCUA SEQ ID NO 107 UUUCUAGUUUGGAGAUGGCAGUUUC SEQ ID NO 86 ACAUCAAGGAAGAUGGCAUUUCUAG SEQ ID NO 108 UUCUAGUUUGGAGAUGGCAGUUUCC SEQ ID NO 87 ACAUCAAGGAAGAUGGCAUUUCUAGUUUGG SEQ ID NO 88 ACAUCAAGGAAGAUGGCAUUUCUAG SEQ ID NO 89 CAUCAAGGAAGAUGGCAUUUCUAGU SEQ ID NO 90 AUCAAGGAAGAUGGCAUUUCUAGUU DMD Gene Exon 53 SEQ ID NO 109 CCAUUGUGUUGAAUCCUUUAACAUU SEQ ID NO 116 CAUUCAACUGUUGCCUCCGGUUCUGAAGGUG SEQ ID NO 110 CCAUUGUGUUGAAUCCUUUAAC SEQ ID NO 117 CUGAAGGUGUUCUUGUACUUCAUCC SEQ ID NO 111 AUUGUGUUGAAUCCUUUAAC SEQ ID NO 118 UGUAUAGGGACCCUCCUUCCAUGACUC SEQ ID NO 112 CCUGUCCUAAGACCUGCUCA SEQ ID NO 119 AUCCCACUGAUUCUGAAUUC SEQ ID NO 113 CUUUUGGAUUGCAUCUACUGUAUAG SEQ ID NO 120 UUGGCUCUGGCCUGUCCUAAGA SEQ ID NO 114 CAUUCAACUGUUGCCUCCGGUUCUG SEQ ID NO 121 AAGACCUGCUCAGCUUCUUCCUUAGCUUCCAGCCA SEQ ID NO 115 CUGUUGCCUCCGGUUCUGAAGGUG DMD Gene Exon 7 SEQ ID NO 122 UGCAUGUUCCAGUCGUUGUGUGG SEQ ID NO 124 AUUUACCAACCUUCAGGAUCGAGUA SEQ ID NO 123 CACUAUUCCAGUCAAAUAGGUCUGG SEQ ID NO 125 GGCCUAAAACACAUACACAUA DMD Gene Exon 44 SEQ ID NO 126 UCAGCUUCUGUUAGCCACUG SEQ ID NO 151 AGCUUCUGUUAGCCACUGAUUAAA SEQ ID NO 127 UUCAGCUUCUGUUAGCCACU SEQ ID NO 152 CAGCUUCUGUUAGCCACUGAUUAAA SEQ ID NO 128 UUCAGCUUCUGUUAGCCACUG SEQ ID NO 153 AGCUUCUGUUAGCCACUGAUUAAA SEQ ID NO 129 UCAGCUUCUGUUAGCCACUGA SEQ ID NO 154 AGCUUCUGUUAGCCACUGAU SEQ ID NO 130 UUCAGCUUCUGUUAGCCACUGA SEQ ID NO 155 GCUUCUGUUAGCCACUGAUU SEQ ID NO 131 UCAGCUUCUGUUAGCCACUGA SEQ ID NO 156 AGCUUCUGUUAGCCACUGAUU SEQ ID NO 132 UUCAGCUUCUGUUAGCCACUGA SEQ ID NO 157 GCUUCUGUUAGCCACUGAUUA SEQ ID NO 133 UCAGCUUCUGUUAGCCACUGAU SEQ ID NO 158 AGCUUCUGUUAGCCACUGAUUA SEQ ID NO 134 UUCAGCUUCUGUUAGCCACUGAU SEQ ID NO 159 GCUUCUGUUAGCCACUGAUUAA SEQ ID NO 135 UCAGCUUCUGUUAGCCACUGAUU SEQ ID NO 160 AGCUUCUGUUAGCCACUGAUUAA SEQ ID NO 136 UUCAGCUUCUGUUAGCCACUGAUU SEQ ID NO 161 GCUUCUGUUAGCCACUGAUUAAA SEQ ID NO 137 UCAGCUUCUGUUAGCCACUGAUUA SEQ ID NO 162 AGCUUCUGUUAGCCACUGAUUAAA SEQ ID NO 138 UUCAGCUUCUGUUAGCCACUGAUA SEQ ID NO 163 GCUUCUGUUAGCCACUGAUUAAA SEQ ID NO 139 UCAGCUUCUGUUAGCCACUGAUUAA SEQ ID NO 164 CCAUUUGUAUUUAGCAUGUUCCC SEQ ID NO 140 UUCAGCUUCUGUUAGCCACUGAUUAA SEQ ID NO 165 AGAUACCAUUUGUAUUUAGC SEQ ID NO 141 UCAGCUUCUGUUAGCCACUGAUUAAA SEQ ID NO 166 GCCAUUUCUCAACAGAUCU SEQ ID NO 142 UUCAGCUUCUGUUAGCCACUGAUUAAA SEQ ID NO 167 GCCAUUUCUCAACAGAUCUGUCA SEQ ID NO 143 CAGCUUCUGUUAGCCACUG SEQ ID NO 168 AUUCUCAGGAAUUUGUGUCUUUC SEQ ID NO 144 CAGCUUCUGUUAGCCACUGAU SEQ ID NO 169 UCUCAGGAAUUUGUGUCUUUC SEQ ID NO 145 AGCUUCUGUUAGCCACUGAUU SEQ ID NO 170 GUUCAGCUUCUGUUAGCC SEQ ID NO 146 CAGCUUCUGUUAGCCACUGAUU SEQ ID NO 171 CUGAUUAAAUAUCUUUAUAU C SEQ ID NO 147 AGCUUCUGUUAGCCACUGAUUA SEQ ID NO 172 GCCGCCAUUUCUCAACAG SEQ ID NO 148 CAGCUUCUGUUAGCCACUGAUUA SEQ ID NO 173 GUAUUUAGCAUGUUCCCA SEQ ID NO 149 AGCUUCUGUUAGCCACUGAUUAA SEQ ID NO 174 CAGGAAUUUGUGUCUUUC SEQ ID NO 150 CAGCUUCUGUUAGCCACUGAUUAA DMD Gene Exon 46 SEQ ID NO 175 GCUUUUCUUUUAGUUGCUGCUCUUU SEQ ID NO 203 AGGUUCAAGUGGGAUACUAGCAAUG SEQ ID NO 176 CUUUUCUUUUAGUUGCUGCUCUUUU SEQ ID NO 204 GGUUCAAGUGGGAUACUAGCAAUGU SEQ ID NO 177 UUUUCUUUUAGUUGCUGCUCUUUUC SEQ ID NO 205 GUUCAAGUGGGAUACUAGCAAUGUU SEQ ID NO 178 UUUCUUUUAGUUGCUGCUCUUUUCC SEQ ID NO 206 UUCAAGUGGGAUACUAGCAAUGUUA SEQ ID NO 179 UUCUUUUAGUUGCUGCUCUUUUCCA SEQ ID NO 207 UCAAGUGGGAUACUAGCAAUGUUAU SEQ ID NO 180 UCUUUUAGUUGCUGCUCUUUUCCAG SEQ ID NO 208 CAAGUGGGAUACUAGCAAUGUUAUC SEQ ID NO 181 CUUUUAGUUGCUGCUCUUUUCCAGG SEQ ID NO 209 AAGUGGGAUACUAGCAAUGUUAUCU SEQ ID NO 182 UUUUAGUUGCUGCUCUUUUCCAGGU SEQ ID NO 210 AGUGGGAUACUAGCAAUGUUAUCUG SEQ ID NO 183 UUUAGUUGCUGCUCUUUUCCAGGUU SEQ ID NO 211 GUGGGAUACUAGCAAUGUUAUCUGC SEQ ID NO 184 UUAGUUGCUGCUCUUUUCCAGGUUC SEQ ID NO 212 UGGGAUACUAGCAAUGUUAUCUGCU SEQ ID NO 185 UAGUUGCUGCUCUUUUCCAGGUUCA SEQ ID NO 213 GGGAUACUAGCAAUGUUAUCUGCUU SEQ ID NO 186 AGUUGCUGCUCUUUUCCAGGUUCAA SEQ ID NO 214 GGAUACUAGCAAUGUUAUCUGCUUC SEQ ID NO 187 GUUGCUGCUCUUUUCCAGGUUCAAG SEQ ID NO 215 GAUACUAGCAAUGUUAUCUGCUUCC SEQ ID NO 188 UUGCUGCUCUUUUCCAGGUUCAAGU SEQ ID NO 216 AUACUAGCAAUGUUAUCUGCUUCCU SEQ ID NO 189 UGCUGCUCUUUUCCAGGUUCAAGUG SEQ ID NO 217 UACUAGCAAUGUUAUCUGCUUCCUC SEQ ID NO 190 GCUGCUCUUUUCCAGGUUCAAGUGG SEQ ID NO 218 ACUAGCAAUGUUAUCUGCUUCCUCC SEQ ID NO 191 CUGCUCUUUUCCAGGUUCAAGUGGG SEQ ID NO 219 CUAGCAAUGUUAUCUGCUUCCUCCA SEQ ID NO 192 UGCUCUUUUCCAGGUUCAAGUGGGA SEQ ID NO 220 UAGCAAUGUUAUCUGCUUCCUCCAA SEQ ID NO 193 GCUCUUUUCCAGGUUCAAGUGGGAC SEQ ID NO 221 AGCAAUGUUAUCUGCUUCCUCCAAC SEQ ID NO 194 CUCUUUUCCAGGUUCAAGUGGGAUA SEQ ID NO 222 GCAAUGUUAUCUGCUUCCUCCAACC SEQ ID NO 195 UCUUUUCCAGGUUCAAGUGGGAUAC SEQ ID NO 223 CAAUGUUAUCUGCUUCCUCCAACCA SEQ ID NO 196 CUUUUCCAGGUUCAAGUGGGAUACU SEQ ID NO 224 AAUGUUAUCUGCUUCCUCCAACCAU SEQ ID NO 197 UUUUCCAGGUUCAAGUGGGAUACUA SEQ ID NO 225 AUGUUAUCUGCUUCCUCCAACCAUA SEQ ID NO 198 UUUCCAGGUUCAAGUGGGAUACUAG SEQ ID NO 226 UGUUAUCUGCUUCCUCCAACCAUAA SEQ ID NO 199 UUCCAGGUUCAAGUGGGAUACUAGC SEQ ID NO 227 GUUAUCUGCUUCCUCCAACCAUAAA SEQ ID NO 200 UCCAGGUUCAAGUGGGAUACUAGCA SEQ ID NO 228 GCUGCUCUUUUCCAGGUUC SEQ ID NO 201 CCAGGUUCAAGUGGGAUACUAGCAA SEQ ID NO 229 UCUUUUCCAGGUUCAAGUGG SEQ ID NO 202 CAGGUUCAAGUGGGAUACUAGCAAU SEQ ID NO 230 AGGUUCAAGUGGGAUACUA DMD Gene Exon 59 SEQ ID NO 231 CAAUUUUUCCCACUCAGUAUU SEQ ID NO 233 UCCUCAGGAGGCAGCUCUAAAU SEQ ID NO 232 UUGAAGUUCCUGGAGUCUU DMD Gene Exon 67 SEQ ID NO 234 GCGCUGGUCACAAAAUCCUGUUGAAC SEQ ID NO 236 GGUGAAUAACUUACAAAUUUGGAAGC SEQ ID NO 235 CACUUGCUUGAAAAGGUCUACAAAGGA
Claims (4)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/229,821 US20190119679A1 (en) | 2007-10-26 | 2018-12-21 | METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA |
US16/283,458 US20190177725A1 (en) | 2007-10-26 | 2019-02-22 | METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA |
US16/584,115 US11427820B2 (en) | 2007-10-26 | 2019-09-26 | Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA |
US17/814,781 US20230151362A1 (en) | 2007-10-26 | 2022-07-25 | Methods and means for efficient dkipping of exon 45 in duchenne muscular dystrophy pre-mrna |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07119351 | 2007-10-26 | ||
PCT/NL2008/050673 WO2009054725A2 (en) | 2007-10-26 | 2008-10-27 | Means and methods for counteracting muscle disorders |
PCT/NL2009/050006 WO2010050801A1 (en) | 2008-10-27 | 2009-01-13 | Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mrna |
US13/094,548 US9926557B2 (en) | 2007-10-26 | 2011-04-26 | Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA |
US14/097,210 US20140113955A1 (en) | 2007-10-26 | 2013-12-04 | METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA |
US14/134,971 US20140128592A1 (en) | 2007-10-26 | 2013-12-19 | METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA |
US14/200,251 US20140221458A1 (en) | 2007-10-26 | 2014-03-07 | METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA |
US14/542,183 US9528109B2 (en) | 2007-10-26 | 2014-11-14 | Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mRNA |
US15/390,836 US20170107512A1 (en) | 2007-10-26 | 2016-12-27 | METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA |
US16/229,821 US20190119679A1 (en) | 2007-10-26 | 2018-12-21 | METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/390,836 Continuation US20170107512A1 (en) | 2007-10-26 | 2016-12-27 | METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/283,458 Continuation US20190177725A1 (en) | 2007-10-26 | 2019-02-22 | METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190119679A1 true US20190119679A1 (en) | 2019-04-25 |
Family
ID=39045623
Family Applications (18)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/767,702 Ceased US9243245B2 (en) | 2007-10-26 | 2010-04-26 | Means and methods for counteracting muscle disorders |
US13/094,548 Active US9926557B2 (en) | 2007-10-26 | 2011-04-26 | Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA |
US13/094,571 Abandoned US20110263682A1 (en) | 2007-10-26 | 2011-04-26 | Methods and means for efficient skipping of at least one of the following exons of the human duchenne muscular dystrophy gene: 43, 46, 50-53 |
US14/097,210 Abandoned US20140113955A1 (en) | 2007-10-26 | 2013-12-04 | METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA |
US14/134,971 Abandoned US20140128592A1 (en) | 2007-10-26 | 2013-12-19 | METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA |
US14/200,251 Abandoned US20140221458A1 (en) | 2007-10-26 | 2014-03-07 | METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA |
US14/542,183 Active US9528109B2 (en) | 2007-10-26 | 2014-11-14 | Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mRNA |
US14/631,686 Active US9499818B2 (en) | 2007-10-26 | 2015-02-25 | Methods and means for efficient skipping of at least one of the exons 51-53, 55, 57 and 59 of the human duchenne muscular dystrophy gene |
US14/990,712 Abandoned US20160304864A1 (en) | 2007-10-26 | 2016-01-07 | Means and methods for counteracting muscle disorders |
US15/289,053 Abandoned US20170044534A1 (en) | 2007-10-26 | 2016-10-07 | Methods and means for efficient skipping of at least one of the following exons of the human duchenne muscular dystrophy gene: 43, 46, 50-53 |
US15/390,836 Abandoned US20170107512A1 (en) | 2007-10-26 | 2016-12-27 | METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA |
US16/024,558 Active US10876114B2 (en) | 2007-10-26 | 2018-06-29 | Methods and means for efficient skipping of at least one of the following exons of the human Duchenne muscular dystrophy gene: 43, 46, 50-53 |
US16/229,534 Abandoned US20190112604A1 (en) | 2007-10-26 | 2018-12-21 | METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA |
US16/229,821 Abandoned US20190119679A1 (en) | 2007-10-26 | 2018-12-21 | METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA |
US16/283,458 Abandoned US20190177725A1 (en) | 2007-10-26 | 2019-02-22 | METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA |
US16/584,115 Active US11427820B2 (en) | 2007-10-26 | 2019-09-26 | Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA |
US17/129,117 Abandoned US20210139904A1 (en) | 2007-10-26 | 2020-12-21 | Methods and means for efficient skipping of at least one of the following exons of the human duchenne muscular dystrophy gene: 43, 46, 50-53 |
US17/814,781 Pending US20230151362A1 (en) | 2007-10-26 | 2022-07-25 | Methods and means for efficient dkipping of exon 45 in duchenne muscular dystrophy pre-mrna |
Family Applications Before (13)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/767,702 Ceased US9243245B2 (en) | 2007-10-26 | 2010-04-26 | Means and methods for counteracting muscle disorders |
US13/094,548 Active US9926557B2 (en) | 2007-10-26 | 2011-04-26 | Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA |
US13/094,571 Abandoned US20110263682A1 (en) | 2007-10-26 | 2011-04-26 | Methods and means for efficient skipping of at least one of the following exons of the human duchenne muscular dystrophy gene: 43, 46, 50-53 |
US14/097,210 Abandoned US20140113955A1 (en) | 2007-10-26 | 2013-12-04 | METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA |
US14/134,971 Abandoned US20140128592A1 (en) | 2007-10-26 | 2013-12-19 | METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA |
US14/200,251 Abandoned US20140221458A1 (en) | 2007-10-26 | 2014-03-07 | METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA |
US14/542,183 Active US9528109B2 (en) | 2007-10-26 | 2014-11-14 | Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mRNA |
US14/631,686 Active US9499818B2 (en) | 2007-10-26 | 2015-02-25 | Methods and means for efficient skipping of at least one of the exons 51-53, 55, 57 and 59 of the human duchenne muscular dystrophy gene |
US14/990,712 Abandoned US20160304864A1 (en) | 2007-10-26 | 2016-01-07 | Means and methods for counteracting muscle disorders |
US15/289,053 Abandoned US20170044534A1 (en) | 2007-10-26 | 2016-10-07 | Methods and means for efficient skipping of at least one of the following exons of the human duchenne muscular dystrophy gene: 43, 46, 50-53 |
US15/390,836 Abandoned US20170107512A1 (en) | 2007-10-26 | 2016-12-27 | METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA |
US16/024,558 Active US10876114B2 (en) | 2007-10-26 | 2018-06-29 | Methods and means for efficient skipping of at least one of the following exons of the human Duchenne muscular dystrophy gene: 43, 46, 50-53 |
US16/229,534 Abandoned US20190112604A1 (en) | 2007-10-26 | 2018-12-21 | METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/283,458 Abandoned US20190177725A1 (en) | 2007-10-26 | 2019-02-22 | METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA |
US16/584,115 Active US11427820B2 (en) | 2007-10-26 | 2019-09-26 | Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA |
US17/129,117 Abandoned US20210139904A1 (en) | 2007-10-26 | 2020-12-21 | Methods and means for efficient skipping of at least one of the following exons of the human duchenne muscular dystrophy gene: 43, 46, 50-53 |
US17/814,781 Pending US20230151362A1 (en) | 2007-10-26 | 2022-07-25 | Methods and means for efficient dkipping of exon 45 in duchenne muscular dystrophy pre-mrna |
Country Status (17)
Country | Link |
---|---|
US (18) | US9243245B2 (en) |
EP (4) | EP3238737B1 (en) |
JP (6) | JP5600064B2 (en) |
CN (5) | CN101896186A (en) |
AU (1) | AU2008317566B2 (en) |
CA (1) | CA2704049A1 (en) |
CY (2) | CY1117286T1 (en) |
DK (1) | DK2203173T3 (en) |
ES (5) | ES2564563T3 (en) |
HK (2) | HK1185098A1 (en) |
HR (1) | HRP20160025T1 (en) |
HU (2) | HUE028662T2 (en) |
IL (4) | IL205322A (en) |
NZ (2) | NZ584793A (en) |
PL (1) | PL2203173T3 (en) |
PT (1) | PT2203173E (en) |
WO (1) | WO2009054725A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US11369689B2 (en) | 2018-08-02 | 2022-06-28 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US11679161B2 (en) | 2021-07-09 | 2023-06-20 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US11787869B2 (en) | 2018-08-02 | 2023-10-17 | Dyne Therapeutics, Inc. | Methods of using muscle targeting complexes to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy or a disease associated with muscle weakness |
Families Citing this family (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1191097A1 (en) * | 2000-09-21 | 2002-03-27 | Leids Universitair Medisch Centrum | Induction of exon skipping in eukaryotic cells |
WO2004083432A1 (en) | 2003-03-21 | 2004-09-30 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
SI3345895T1 (en) | 2003-04-11 | 2020-03-31 | Ptc Therapeutics, Inc. | 1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and the treatment of disease |
USRE48960E1 (en) | 2004-06-28 | 2022-03-08 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
EP2206781B1 (en) | 2004-06-28 | 2015-12-02 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
WO2006086667A2 (en) | 2005-02-09 | 2006-08-17 | Avi Bio Pharma, Inc. | Antisense composition and method for treating muscle atrophy |
NZ574807A (en) | 2006-08-11 | 2011-01-28 | Prosensa Technologies Bv | Methods and means for treating dna repeat instability associated genetic disorders |
CN101896186A (en) | 2007-10-26 | 2010-11-24 | 莱顿教学医院 | The mode and the method for antagonism disorder of muscle |
EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
US8084601B2 (en) | 2008-09-11 | 2011-12-27 | Royal Holloway And Bedford New College Royal Holloway, University Of London | Oligomers |
SI3133160T1 (en) | 2008-10-24 | 2019-05-31 | Sarepta Therapeutics, Inc. | Exon skipping compositions for dmd |
DK2607484T3 (en) * | 2008-10-27 | 2016-03-07 | Biomarin Technologies B V | Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-MRNA |
ES2593836T3 (en) | 2009-04-24 | 2016-12-13 | Biomarin Technologies B.V. | Oligonucleotide comprising an inosine to treat DMD |
US20120270930A1 (en) | 2009-10-29 | 2012-10-25 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Methods and compositions for dysferlin exon-skipping |
ES2693459T3 (en) | 2009-11-12 | 2018-12-11 | The University Of Western Australia | Antisense molecules and methods for the treatment of pathologies |
AU2011286539B2 (en) * | 2010-08-05 | 2017-03-02 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Antisense oligonucleotide directed removal of proteolytic cleavage sites from proteins |
TWI541024B (en) | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | Antisense nucleic acid |
WO2012109296A1 (en) | 2011-02-08 | 2012-08-16 | The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center | Antisense oligonucleotides |
CA2831827A1 (en) | 2011-04-05 | 2012-10-11 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Compounds and methods for altering activin receptor-like kinase signalling |
JP5850519B2 (en) * | 2011-05-09 | 2016-02-03 | ネッパジーン株式会社 | A therapeutic agent for muscular dystrophy containing morpholino-loaded bubble liposomes as active ingredients |
WO2013016595A1 (en) * | 2011-07-28 | 2013-01-31 | The Regents Of The University Of California | Exonic splicing enhancers and exonic splicing silencers |
US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
EP2799548B1 (en) | 2011-12-28 | 2019-08-21 | Nippon Shinyaku Co., Ltd. | Antisense nucleic acid |
EP4043039A1 (en) * | 2012-01-27 | 2022-08-17 | BioMarin Technologies B.V. | Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy |
DE102012103041A1 (en) | 2012-04-10 | 2013-10-10 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | New isolated antisense-oligonucleotide comprising sequence that is hybridized to messenger RNA-splicing-sequence of mutation-bearing exons of pre-messenger RNA of titin-gene and induces skipping of exons, used to treat heart disease |
WO2013163628A2 (en) | 2012-04-27 | 2013-10-31 | Duke University | Genetic correction of mutated genes |
CA2877644A1 (en) * | 2012-07-03 | 2014-01-09 | Prosensa Technologies B.V. | Oligonucleotide for the treatment of muscular dystrophy patients |
EP3633035A1 (en) | 2013-03-14 | 2020-04-08 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
MX366274B (en) * | 2013-03-14 | 2019-07-04 | Sarepta Therapeutics Inc | Exon skipping compositions for treating muscular dystrophy. |
BR112015022998A2 (en) * | 2013-03-15 | 2017-11-14 | Sarepta Therapeutics Inc | improved compositions for treating muscular dystrophy |
US9849066B2 (en) | 2013-04-24 | 2017-12-26 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
EP3004370B1 (en) | 2013-06-05 | 2024-08-21 | Duke University | Rna-guided gene editing and gene regulation |
CA2942147C (en) | 2014-03-06 | 2022-12-13 | Ptc Therapeutics, Inc. | Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid |
TR201901939T4 (en) | 2014-03-12 | 2019-03-21 | Nat Center Neurology & Psychiatry | Antisense nucleic acid. |
GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
MX2016016526A (en) | 2014-06-17 | 2017-04-04 | Nippon Shinyaku Co Ltd | Antisense nucleic acid. |
CN106714845A (en) * | 2014-08-11 | 2017-05-24 | 得克萨斯州大学系统董事会 | Prevention of muscular dystrophy by crispr/cas9-mediated gene editing |
CA2963288A1 (en) | 2014-10-03 | 2016-04-07 | Cold Spring Harbor Laboratory | Targeted augmentation of nuclear gene output |
JP6929791B2 (en) | 2015-02-09 | 2021-09-01 | デューク ユニバーシティ | Compositions and methods for epigenome editing |
MA41795A (en) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | EXCLUSION OF AN EXON INDUCED BY ANTISENSE COMPOUNDS IN MYOSTATIN |
EA036393B1 (en) * | 2015-05-21 | 2020-11-05 | Вингс Терапьютикс, Инк. | Antisense oligonucleotides to treat dystrophic epidermolysis bullosa |
US10471089B2 (en) * | 2015-06-10 | 2019-11-12 | Association Institut De Myologie | Combined therapy for duchenne muscular dystrophy |
EP3325018A4 (en) | 2015-07-22 | 2019-04-24 | Duke University | High-throughput screening of regulatory element function with epigenome editing technologies |
EP3341727B1 (en) | 2015-08-25 | 2022-08-10 | Duke University | Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases |
WO2017047707A1 (en) | 2015-09-15 | 2017-03-23 | 日本新薬株式会社 | Antisense nucleic acid |
AU2016334232B2 (en) * | 2015-10-09 | 2022-05-26 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
US10196639B2 (en) | 2015-10-09 | 2019-02-05 | University Of Southampton | Modulation of gene expression and screening for deregulated protein expression |
CN108699555A (en) | 2015-10-09 | 2018-10-23 | 萨勒普塔医疗公司 | Composition for treating Duchenne's dystrophy and associated disease and method |
WO2017066497A2 (en) | 2015-10-13 | 2017-04-20 | Duke University | Genome engineering with type i crispr systems in eukaryotic cells |
AR106530A1 (en) | 2015-10-30 | 2018-01-24 | Ptc Therapeutics Inc | METHODS TO TREAT EPILEPSY |
EP3390636B1 (en) | 2015-12-14 | 2021-05-19 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of dravet syndrome |
US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
GB2545898B (en) | 2015-12-21 | 2019-10-09 | Sutura Therapeutics Ltd | Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides |
GB2574525B (en) * | 2015-12-21 | 2020-09-02 | Sutura Therapeutics Ltd | Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides |
MA45328A (en) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF |
LT3442600T (en) * | 2016-04-15 | 2024-05-27 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery of b-sarcoglycan and microrna-29 and the treatment of muscular dystrophy |
MA45290A (en) * | 2016-05-04 | 2019-03-13 | Wave Life Sciences Ltd | PROCESSES AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS |
WO2018005805A1 (en) * | 2016-06-30 | 2018-01-04 | Sarepta Therapeutics, Inc. | Exon skipping oligomers for muscular dystrophy |
DK3554553T3 (en) | 2016-12-19 | 2022-09-19 | Sarepta Therapeutics Inc | EXON-SKIPPING OLIGOMER CONJUGATE FOR MUSCULAR DYSTROPHY |
MX2019006989A (en) | 2016-12-19 | 2019-08-16 | Sarepta Therapeutics Inc | Exon skipping oligomer conjugates for muscular dystrophy. |
PL3554552T3 (en) | 2016-12-19 | 2022-11-21 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
SG11201906200WA (en) | 2017-01-06 | 2019-08-27 | Avidity Biosciences Llc | Nucleic acid-polypeptide compositions and methods of inducing exon skipping |
JP2020513811A (en) * | 2017-03-17 | 2020-05-21 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | Adeno-associated virus vector delivery of muscle-specific microdystrophin for treating muscular dystrophy |
EP3612546B1 (en) * | 2017-04-20 | 2022-07-13 | Synthena AG | Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof |
GB201711809D0 (en) * | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
CN111499615B (en) | 2017-08-04 | 2024-02-02 | 斯基霍克疗法公司 | Methods and compositions for modulating splicing |
WO2019040923A1 (en) | 2017-08-25 | 2019-02-28 | Stoke Therapeutics, Inc. | Antisense oligomers for treatment of conditions and diseases |
EA201991450A1 (en) | 2017-09-22 | 2019-12-30 | Сарепта Терапьютикс, Инк. | OLIGOMER CONJUGATES FOR EXONISM SKIP IN MUSCULAR DYSTROPHY |
CN111770757A (en) * | 2017-09-22 | 2020-10-13 | 艾维迪提生物科学公司 | Nucleic acid-polypeptide compositions and methods for inducing exon skipping |
JP2020536060A (en) | 2017-09-28 | 2020-12-10 | サレプタ セラピューティクス, インコーポレイテッド | Combination therapy to treat muscular dystrophy |
WO2019067979A1 (en) | 2017-09-28 | 2019-04-04 | Sarepta Therapeutics, Inc. | Combination therapies for treating muscular dystrophy |
JP2020536058A (en) | 2017-09-28 | 2020-12-10 | サレプタ セラピューティクス, インコーポレイテッド | Combination therapy to treat muscular dystrophy |
AU2018378812A1 (en) | 2017-12-06 | 2020-07-09 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle atrophy and myotonic dystrophy |
CN112004533A (en) * | 2018-02-20 | 2020-11-27 | 艾知怀斯治疗学公司 | Methods and compositions for treating movement disorders |
AU2019252680A1 (en) * | 2018-04-12 | 2020-10-22 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
MX2020011695A (en) | 2018-05-04 | 2021-02-26 | Stoke Therapeutics Inc | Methods and compositions for treatment of cholesteryl ester storage disease. |
US10765760B2 (en) | 2018-05-29 | 2020-09-08 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
US20220251551A1 (en) * | 2018-06-13 | 2022-08-11 | Sarepta Therapeutics, Inc. | Exon skipping oligomers for muscular dystrophy |
TW202020153A (en) * | 2018-07-27 | 2020-06-01 | 美商薩羅塔治療公司 | Exon skipping oligomers for muscular dystrophy |
CN109486813B (en) * | 2018-10-10 | 2022-01-18 | 广州医科大学附属第二医院 | U1-snRNA for repairing abnormal splicing of PremRNA of TPP1 gene and application thereof |
CN113383078A (en) * | 2018-12-06 | 2021-09-10 | 波涛生命科学有限公司 | Oligonucleotide compositions and methods thereof |
EP3920915A4 (en) | 2019-02-05 | 2022-10-05 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
EP3920928A4 (en) | 2019-02-06 | 2022-09-28 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
JP2022526643A (en) * | 2019-04-10 | 2022-05-25 | ピーティーシー セラピューティクス,インコーポレーテッド | Methods for treating Duchenne muscular dystrophy mediated by nonsense mutations in pediatric patients |
CN110288555B (en) * | 2019-07-02 | 2022-08-02 | 桂林电子科技大学 | Low-illumination enhancement method based on improved capsule network |
CN114466682A (en) * | 2019-08-02 | 2022-05-10 | 全国儿童医院研究所 | Nucleic acids targeting exon 44 for the treatment of dystrophin-based myopathy and recombinant adeno-associated viruses comprising the same |
EP4031242A4 (en) * | 2019-09-19 | 2023-12-20 | Arnay Sciences, Llc | Compounds and methods useful for modulating gene splicing |
US20230140736A1 (en) | 2020-02-28 | 2023-05-04 | Nippon Shinyaku Co., Ltd. | Antisense nucleic acid inducing skipping of exon 51 |
CA3172111A1 (en) | 2020-03-19 | 2021-09-23 | Barbora MALECOVA | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
EP4150092A1 (en) | 2020-05-11 | 2023-03-22 | Stoke Therapeutics, Inc. | Opa1 antisense oligomers for treatment of conditions and diseases |
JP2024519601A (en) | 2021-03-31 | 2024-05-20 | エントラーダ セラピューティクス,インコーポレイティド | Cyclic cell-penetrating peptides |
WO2022241408A1 (en) | 2021-05-10 | 2022-11-17 | Entrada Therapeutics, Inc. | Compositions and methods for modulating tissue distribution of intracellular therapeutics |
EP4088722A1 (en) * | 2021-05-12 | 2022-11-16 | Justus-Liebig-Universität Gießen | Pharmaceutical compositions, uses thereof and methods for treatment of genetic diseases caused by intronic splice-acceptor site mutations |
WO2022271818A1 (en) | 2021-06-23 | 2022-12-29 | Entrada Therapeutics, Inc. | Antisense compounds and methods for targeting cug repeats |
EP4367247A2 (en) * | 2021-07-09 | 2024-05-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
AU2022345098A1 (en) | 2021-09-16 | 2024-04-04 | Avidity Biosciences, Inc. | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
EP4215614A1 (en) | 2022-01-24 | 2023-07-26 | Dynacure | Combination therapy for dystrophin-related diseases |
WO2023168427A1 (en) | 2022-03-03 | 2023-09-07 | Yale University | Compositions and methods for delivering therapeutic polynucleotides for exon skipping |
US12071621B2 (en) | 2022-04-05 | 2024-08-27 | Avidity Biosciences, Inc. | Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping |
WO2023250511A2 (en) | 2022-06-24 | 2023-12-28 | Tune Therapeutics, Inc. | Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression |
WO2024069229A2 (en) | 2022-08-03 | 2024-04-04 | Sutura Therapeutics Ltd | Biologically active compounds |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006000057A1 (en) * | 2004-06-28 | 2006-01-05 | SMITHKLINE BEECHAM CORPORATION, doing business as GLAXOSMITHKLINE | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
US20130211062A1 (en) * | 2010-09-01 | 2013-08-15 | National Center Of Neurology And Psychiatry | Antisense nucleic acids |
US20140315977A1 (en) * | 2013-03-14 | 2014-10-23 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
Family Cites Families (217)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2752581C2 (en) | 1977-11-25 | 1979-12-13 | Wolfgang 4044 Kaarst Keil | Device for the complete demineralisation of water |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5541308A (en) | 1986-11-24 | 1996-07-30 | Gen-Probe Incorporated | Nucleic acid probes for detection and/or quantitation of non-viral organisms |
DE3834636A1 (en) | 1988-10-11 | 1990-04-19 | Max Planck Gesellschaft | METHOD FOR ANALYZING LENGTH POLYMORPHISMS IN DNA AREAS |
US5766847A (en) | 1988-10-11 | 1998-06-16 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Process for analyzing length polymorphisms in DNA regions |
US6867195B1 (en) | 1989-03-21 | 2005-03-15 | Vical Incorporated | Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected |
US5681941A (en) | 1990-01-11 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Substituted purines and oligonucleotide cross-linking |
US5608046A (en) | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
FR2675803B1 (en) | 1991-04-25 | 1996-09-06 | Genset Sa | CLOSED, ANTISENSE AND SENSE OLIGONUCLEOTIDES AND THEIR APPLICATIONS. |
JPH07501204A (en) | 1991-06-28 | 1995-02-09 | マサチューセッツ インスティテュート オブ テクノロジー | Topical oligonucleotide therapy |
EP0558697A1 (en) | 1991-06-28 | 1993-09-08 | Massachusetts Institute Of Technology | Localized oligonucleotide therapy |
US6200747B1 (en) | 1992-01-28 | 2001-03-13 | North Shore University Hospital Research Corp. | Method and kits for detection of fragile X specific, GC-rich DNA sequences |
US5869252A (en) | 1992-03-31 | 1999-02-09 | Abbott Laboratories | Method of multiplex ligase chain reaction |
US6172208B1 (en) | 1992-07-06 | 2001-01-09 | Genzyme Corporation | Oligonucleotides modified with conjugate groups |
US5418139A (en) | 1993-02-10 | 1995-05-23 | University Of Iowa Research Foundation | Method for screening for cardiomyopathy |
CA2116280A1 (en) | 1993-03-05 | 1994-09-06 | Marcy E. Macdonald | Huntingtin dna, protein and uses thereof |
PT698092E (en) | 1993-05-11 | 2007-10-29 | Univ North Carolina | Antisense oligonucleotides which combat aberrant splicing and methods of using the same |
US5695933A (en) | 1993-05-28 | 1997-12-09 | Massachusetts Institute Of Technology | Direct detection of expanded nucleotide repeats in the human genome |
US5741645A (en) | 1993-06-29 | 1998-04-21 | Regents Of The University Of Minnesota | Gene sequence for spinocerebellar ataxia type 1 and method for diagnosis |
US5624803A (en) | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
US5627263A (en) | 1993-11-24 | 1997-05-06 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
DE4342605A1 (en) | 1993-12-14 | 1995-06-22 | Buna Gmbh | Functionalized olefin homo- and copolymers |
US5962332A (en) | 1994-03-17 | 1999-10-05 | University Of Massachusetts | Detection of trinucleotide repeats by in situ hybridization |
AU2360195A (en) | 1994-05-05 | 1995-11-29 | Beckman Instruments, Inc. | Oligonucleotide repeat arrays |
US5968909A (en) | 1995-08-04 | 1999-10-19 | Hybridon, Inc. | Method of modulating gene expression with reduced immunostimulatory response |
US5854223A (en) | 1995-10-06 | 1998-12-29 | The Trustees Of Columbia University In The City Of New York | S-DC28 as an antirestenosis agent after balloon injury |
US20070173465A9 (en) | 1995-10-11 | 2007-07-26 | Monahan Sean D | Expression of zeta negative and zeta positive nucleic acids using a dystrophin gene |
US7034009B2 (en) | 1995-10-26 | 2006-04-25 | Sirna Therapeutics, Inc. | Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R) |
US6300060B1 (en) | 1995-11-09 | 2001-10-09 | Dana-Farber Cancer Institute, Inc. | Method for predicting the risk of prostate cancer morbidity and mortality |
DK0882061T3 (en) | 1996-02-14 | 2004-09-27 | Isis Pharmaceuticals Inc | Sugar modified gapped oligonucleotides |
AU6469896A (en) | 1996-07-18 | 1998-02-10 | Srl Inc. | Method for the diagnosis of spinocerebellar ataxia type 2 and primers therefor |
CA2241173A1 (en) | 1996-10-30 | 1998-05-07 | Srl, Inc. | Cdna fragment of causative gene of spinocerebellar ataxia type 2 |
US5853995A (en) | 1997-01-07 | 1998-12-29 | Research Development Foundation | Large scale genotyping of diseases and a diagnostic test for spinocerebellar ataxia type 6 |
AU6591798A (en) | 1997-03-31 | 1998-10-22 | Yale University | Nucleic acid catalysts |
US20020137890A1 (en) | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
AU7265298A (en) | 1997-04-29 | 1998-11-24 | Trustees Of Boston University | Methods and compositions for targeted dna differential display |
US6329501B1 (en) | 1997-05-29 | 2001-12-11 | Auburn University | Methods and compositions for targeting compounds to muscle |
US6280938B1 (en) | 1997-08-19 | 2001-08-28 | Regents Of The University Of Minnesota | SCA7 gene and method of use |
US6514755B1 (en) | 1998-08-18 | 2003-02-04 | Regents Of The University Of Minnesota | SCA7 gene and methods of use |
US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
CA2304813A1 (en) | 1997-09-22 | 1999-04-08 | Fritz Eckstein | Nucleic acid catalysts with endonuclease activity |
US6130207A (en) | 1997-11-05 | 2000-10-10 | South Alabama Medical Science Foundation | Cell-specific molecule and method for importing DNA into a nucleus |
JP3012923B2 (en) | 1998-01-26 | 2000-02-28 | 新潟大学長 | Drug for treating CAG repeat disease |
KR100280219B1 (en) | 1998-02-26 | 2001-04-02 | 이수빈 | Diagnostic Method and Diagnostic Reagent of Neuropsychiatric Disease Using Trinucleic Acid Repeat Sequence |
US6322978B1 (en) | 1998-04-20 | 2001-11-27 | Joslin Diabetes Center, Inc. | Repeat polymorphism in the frataxin gene and uses therefore |
EP1073732A2 (en) | 1998-04-29 | 2001-02-07 | Ribozyme Pharmaceuticals, Inc. | Nucleoside triphosphates and their incorporation into ribozymes |
CA2334960C (en) | 1998-06-10 | 2012-01-03 | Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh | Combination of tgf-.beta. inhibition and immune stimulation to treat hyperproliferative diseases |
US6924355B2 (en) | 1998-09-01 | 2005-08-02 | Genentech, Inc. | PRO1343 polypeptides |
JP2002525382A (en) | 1998-09-25 | 2002-08-13 | ザ チルドレンズ メディカル センター コーポレイション | Short peptide that selectively regulates protein kinase activity |
US6172216B1 (en) | 1998-10-07 | 2001-01-09 | Isis Pharmaceuticals Inc. | Antisense modulation of BCL-X expression |
US6210892B1 (en) | 1998-10-07 | 2001-04-03 | Isis Pharmaceuticals, Inc. | Alteration of cellular behavior by antisense modulation of mRNA processing |
DE69932346T2 (en) * | 1998-10-26 | 2007-07-05 | Avi Biopharma, Inc., Portland | Morpholine-based p53 antisense oligonucleotide and its uses |
US6399575B1 (en) | 1998-11-10 | 2002-06-04 | Auburn University | Methods and compositions for targeting compounds to the central nervous system |
US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
US20040226056A1 (en) | 1998-12-22 | 2004-11-11 | Myriad Genetics, Incorporated | Compositions and methods for treating neurological disorders and diseases |
US20020049173A1 (en) | 1999-03-26 | 2002-04-25 | Bennett C. Frank | Alteration of cellular behavior by antisense modulation of mRNA processing |
US6379698B1 (en) | 1999-04-06 | 2002-04-30 | Isis Pharmaceuticals, Inc. | Fusogenic lipids and vesicles |
CA2365984A1 (en) | 1999-04-08 | 2000-10-19 | Oasis Biosciences, Inc. | Antisense oligonucleotides comprising universal and/or degenerate bases |
JP2000325085A (en) | 1999-05-21 | 2000-11-28 | Masafumi Matsuo | Pharmaceutical composition for treatment of duchenne muscular dystrophy |
US20030236214A1 (en) | 1999-06-09 | 2003-12-25 | Wolff Jon A. | Charge reversal of polyion complexes and treatment of peripheral occlusive disease |
US6656730B1 (en) | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
WO2000078813A2 (en) | 1999-06-18 | 2000-12-28 | Emory University | Huntington disease cellular model: stably transfected pc12 cells expressing mutant huntingtin |
WO2001016312A2 (en) | 1999-08-31 | 2001-03-08 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid based modulators of gene expression |
CA2386540A1 (en) | 1999-10-04 | 2001-04-12 | University Of Medicine And Dentistry Of New Jersey | Novel carbamates and ureas |
US6165786A (en) | 1999-11-03 | 2000-12-26 | Isis Pharmaceuticals, Inc. | Antisense modulation of nucleolin expression |
EP1257639A2 (en) | 2000-02-08 | 2002-11-20 | Ribozyme Pharmaceuticals, Inc. | Nucleozymes with endonuclease activity |
WO2005019453A2 (en) | 2001-05-18 | 2005-03-03 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) |
EP1133993A1 (en) | 2000-03-10 | 2001-09-19 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Substances for the treatment of spinal muscular atrophy |
US20020187931A1 (en) | 2000-04-13 | 2002-12-12 | Michael Hayden | Modulating cell survival by modulating huntingtin function |
US6653467B1 (en) * | 2000-04-26 | 2003-11-25 | Jcr Pharmaceutical Co., Ltd. | Medicament for treatment of Duchenne muscular dystrophy |
EP1287125B1 (en) | 2000-04-28 | 2009-07-29 | Asklepios Biopharmaceutical, Inc. | Dna sequences encoding dystrophin minigenes and methods of use thereof |
AU5736601A (en) | 2000-05-01 | 2001-11-12 | Hybridon Inc | Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides |
US20020013287A1 (en) | 2000-05-09 | 2002-01-31 | Reliable Biopharmaceuticals, Inc. St Louis Missouri | Polymeric compounds useful as prodrugs |
US7405193B2 (en) | 2000-05-31 | 2008-07-29 | Serono Genetics Institute S.A. | Use of Acrp30 globular head to promote increases in muscle mass and muscle differentiation |
CN1326990A (en) | 2000-06-07 | 2001-12-19 | 上海博德基因开发有限公司 | New polypeptide-human DNA-like CGG repeative conjugated protein 16.17 and polynucleotide for encoding such polypeptide |
US20030124523A1 (en) | 2000-06-22 | 2003-07-03 | Asselbergs Fredericus Alphonsus Maria | Organic compounds |
US6794192B2 (en) | 2000-06-29 | 2004-09-21 | Pfizer Inc. | Target |
RU2165149C1 (en) | 2000-07-03 | 2001-04-20 | Шапошников Валерий Геннадьевич | "sugar wool" products forming and packaging method |
US6727355B2 (en) | 2000-08-25 | 2004-04-27 | Jcr Pharmaceuticals Co., Ltd. | Pharmaceutical composition for treatment of Duchenne muscular dystrophy |
JP4836366B2 (en) | 2000-08-25 | 2011-12-14 | 雅文 松尾 | Duchenne muscular dystrophy treatment |
EP1191097A1 (en) | 2000-09-21 | 2002-03-27 | Leids Universitair Medisch Centrum | Induction of exon skipping in eukaryotic cells |
AU3922802A (en) | 2000-10-02 | 2002-05-27 | Keck Graduate Inst | Methods for identifying nucleotides at defined positions in target nucleic acidsusing fluorescence polarization |
WO2002029056A2 (en) | 2000-10-06 | 2002-04-11 | Regents Of The University Of Michigan | Mini-dystrophin nucleic acid and peptide sequences |
US6623927B1 (en) | 2000-11-08 | 2003-09-23 | Council Of Scientific And Industrial Research | Method of detection of allelic variants of SCA2 gene |
US6743893B2 (en) | 2000-11-30 | 2004-06-01 | The Uab Research Foundation | Receptor-mediated uptake of peptides that bind the human transferrin receptor |
US7001994B2 (en) | 2001-01-18 | 2006-02-21 | Genzyme Corporation | Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins |
TW200526779A (en) | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
KR100408053B1 (en) | 2001-02-13 | 2003-12-01 | 엘지전자 주식회사 | Torque ripple reduction method for srm |
US20070021360A1 (en) * | 2001-04-24 | 2007-01-25 | Nyce Jonathan W | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase |
WO2002092763A2 (en) | 2001-05-11 | 2002-11-21 | Regents Of The University Of Minnesota | Intron associated with myotonic dystrophy type 2 and methods of use |
US20050277133A1 (en) | 2001-05-18 | 2005-12-15 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA) |
US20050282188A1 (en) | 2001-05-18 | 2005-12-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
US20050014172A1 (en) | 2002-02-20 | 2005-01-20 | Ivan Richards | RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA) |
IL143379A (en) | 2001-05-24 | 2013-11-28 | Yissum Res Dev Co | Antisense oligonucleotide against the r isophorm of human ache and uses thereof |
JP4510442B2 (en) | 2001-06-26 | 2010-07-21 | ブリストル−マイヤーズ スクイブ カンパニー | N-heterocyclic inhibitor of TNF-α expression |
NZ530360A (en) | 2001-07-06 | 2006-01-27 | Topigen Pharma Inc | Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals by substituting an adenosine base for 2'6'-diaminopurine (DAP) and analogs thereof |
AU2002326589B2 (en) | 2001-08-07 | 2008-06-05 | University Of Delaware | Compositions and methods for the prevention and treatment of Huntington's disease |
DE60230046D1 (en) | 2001-08-10 | 2009-01-08 | Novartis Ag | PEPTIDES BINDING ATHEROSCLEROTIC INJURIES |
US20060074034A1 (en) | 2001-09-17 | 2006-04-06 | Collins Douglas A | Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof |
KR20030035047A (en) | 2001-10-29 | 2003-05-09 | (주)바이오코돈 | Use of BMP-4 gene and its gene product for treatment and diagnosis of Lichen Planus |
US20030166004A1 (en) | 2001-11-01 | 2003-09-04 | Jeno Gyuris | Endothelial-cell binding peptides for diagnosis and therapy |
US20030134790A1 (en) | 2002-01-11 | 2003-07-17 | University Of Medicine And Dentistry Of New Jersey | Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer |
WO2003062258A1 (en) | 2002-01-22 | 2003-07-31 | The Cleveland Clinic Foundation | Rnase l activator-antisense complexes |
WO2003069330A1 (en) | 2002-02-11 | 2003-08-21 | The Trustees Of Columbia University In The City Of New York | System and method for identifying proteins involved in force-initiated signal transduction |
US20050096284A1 (en) | 2002-02-20 | 2005-05-05 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA) |
DE60331049D1 (en) | 2002-03-01 | 2010-03-11 | Univ Tulane | CONJUGATES OF CYTOTOXIC AGENTS AND BIOLOGICALLY ACTIVE PEPTIDES |
US20040101852A1 (en) | 2002-11-21 | 2004-05-27 | Isis Pharmaceuticals Inc. | Modulation of CGG triplet repeat binding protein 1 expression |
ITRM20020253A1 (en) | 2002-05-08 | 2003-11-10 | Univ Roma | SNRNA CHEMICAL MOLECULES WITH ANTISENSE SEQUENCES FOR SPLICING JUNCTIONS OF THE DYSTROPHINE GENE AND THERAPEUTIC APPLICATIONS. |
US20040102395A1 (en) | 2002-11-22 | 2004-05-27 | Isis Pharmaceuticals Inc. | Modulation of IAP-like expression |
EP1380644A1 (en) | 2002-07-08 | 2004-01-14 | Kylix B.V. | The use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role |
WO2004011060A2 (en) | 2002-07-26 | 2004-02-05 | Mirus Corporation | Delivery of molecules and complexes to mammalian cells in vivo |
US20050255086A1 (en) | 2002-08-05 | 2005-11-17 | Davidson Beverly L | Nucleic acid silencing of Huntington's Disease gene |
CA2493297A1 (en) | 2002-08-12 | 2004-02-19 | Universite De Sherbrooke | Methods to reprogram splice site selection in pre-messenger rnas |
GB0219143D0 (en) | 2002-08-16 | 2002-09-25 | Univ Leicester | Modified tailed oligonucleotides |
US20040219565A1 (en) | 2002-10-21 | 2004-11-04 | Sakari Kauppinen | Oligonucleotides useful for detecting and analyzing nucleic acids of interest |
EP1554305B1 (en) | 2002-10-23 | 2007-03-28 | Centre for Research and Technology Hellas/Institute of Agrobiotechnology | Prion protein-binding peptide sequences |
US7892793B2 (en) | 2002-11-04 | 2011-02-22 | University Of Massachusetts | Allele-specific RNA interference |
US7655785B1 (en) | 2002-11-14 | 2010-02-02 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof |
US7250496B2 (en) * | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
DK2284266T3 (en) | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | SIRNA MOLECULE MOD TP53 |
ES2566632T3 (en) | 2002-11-25 | 2016-04-14 | Masafumi Matsuo | ENA nucleic acid drugs that modify splicing in mRNA precursors |
GB0228079D0 (en) | 2002-12-02 | 2003-01-08 | Laxdale Ltd | Huntington's Disease |
EP3450559A1 (en) | 2003-03-07 | 2019-03-06 | Alnylam Pharmaceuticals, Inc. | Therapeutic compositions |
WO2004083432A1 (en) | 2003-03-21 | 2004-09-30 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
US7514551B2 (en) | 2003-04-03 | 2009-04-07 | Enzo Life Sciences, Inc. | Multisignal labeling reagents, and processes and uses therefor |
WO2004101787A1 (en) | 2003-05-14 | 2004-11-25 | Japan Science And Technology Agency | Inhibition of the expression of huntington gene |
CN1829532A (en) | 2003-06-02 | 2006-09-06 | 惠氏公司 | Use of myostatin (GDF8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders |
ES2302898T3 (en) | 2003-07-11 | 2008-08-01 | Lbr Medbiotech B.V. | TRANSFER OF GENES TO MUSCLE CELLS MEDIATED BY THE MANOSA-6-PHOSPHATE RECEIVER. |
US20050048495A1 (en) | 2003-08-29 | 2005-03-03 | Baker Brenda F. | Isoform-specific targeting of splice variants |
US20050054752A1 (en) | 2003-09-08 | 2005-03-10 | O'brien John P. | Peptide-based diblock and triblock dispersants and diblock polymers |
WO2005033134A2 (en) | 2003-09-30 | 2005-04-14 | Regeneron Pharmaceuticals, Inc. | Secreted protein therapeutics and uses thereof |
WO2005035550A2 (en) | 2003-10-14 | 2005-04-21 | Kernel Biopharma Inc. | Dual phase-pna conjugates for the delivery of pna through the blood brain barrier |
US20050191636A1 (en) | 2004-03-01 | 2005-09-01 | Biocept, Inc. | Detection of STRP, such as fragile X syndrome |
US20080207538A1 (en) | 2004-03-11 | 2008-08-28 | Lawrence David S | Enhanced Production of Functional Proteins From Defective Genes |
EP1735443A2 (en) | 2004-04-14 | 2006-12-27 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED TREATMENT OF POLYGLUTAMINE (POLYQ) REPEAT EXPANSION DISEASES USING SHORT INTERFERING NUCLEIC ACID (siNA) |
KR20070085113A (en) | 2004-05-11 | 2007-08-27 | 가부시키가이샤 알파젠 | Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same |
US20050288246A1 (en) | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
WO2005115439A2 (en) | 2004-05-27 | 2005-12-08 | Acceleron Pharma Inc. | Cerberus/coco derivatives and uses thereof |
US7361468B2 (en) * | 2004-07-02 | 2008-04-22 | Affymetrix, Inc. | Methods for genotyping polymorphisms in humans |
EP1618881A1 (en) * | 2004-07-20 | 2006-01-25 | Santhera Pharmaceuticals (Schweiz) GmbH | Use of non-glucocorticoid steroids for the treatment of muscular dystrophy |
WO2006017522A2 (en) | 2004-08-03 | 2006-02-16 | University Of Utah Research Foundation | Use of antisense oligonucleotides to effect translation modulation |
US20060099612A1 (en) | 2004-09-02 | 2006-05-11 | Suntory Limited | Method for analyzing genes of industrial yeasts |
CA2582137A1 (en) | 2004-10-05 | 2007-02-15 | Wyeth | Probe arrays for detecting multiple strains of different species |
ITRM20040568A1 (en) | 2004-11-18 | 2005-02-18 | Uni Degli Studi Di Roma Tor Vergata | USE OF THE "PHAGE DISPLAY" TECHNIQUE FOR THE IDENTIFICATION OF PEPTIDES WITH CAPACITY OF STAMIN CELLS / PROGENITOR, PEPTIDES SO OBTAINED AND THEIR USES. |
US7838657B2 (en) | 2004-12-03 | 2010-11-23 | University Of Massachusetts | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
KR100663277B1 (en) | 2004-12-20 | 2007-01-02 | 삼성전자주식회사 | Device and?method for processing system-related event in wireless terminal |
US20060148740A1 (en) | 2005-01-05 | 2006-07-06 | Prosensa B.V. | Mannose-6-phosphate receptor mediated gene transfer into muscle cells |
US20120122801A1 (en) | 2005-01-05 | 2012-05-17 | Prosensa B.V. | Mannose-6-phosphate receptor mediated gene transfer into muscle cells |
CA2596588C (en) | 2005-01-31 | 2017-06-27 | University Of Iowa Research Foundation | Nucleic acid silencing of huntington's disease gene |
PL1877099T3 (en) | 2005-04-06 | 2013-02-28 | Genzyme Corp | Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety |
WO2006112705A2 (en) | 2005-04-22 | 2006-10-26 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the binding of sr proteins and by interfering with secondary rna structure. |
WO2006121960A2 (en) | 2005-05-06 | 2006-11-16 | Medtronic, Inc. | Methods and sequences to suppress primate huntington gene expression |
US7902352B2 (en) | 2005-05-06 | 2011-03-08 | Medtronic, Inc. | Isolated nucleic acid duplex for reducing huntington gene expression |
WO2006121277A1 (en) | 2005-05-09 | 2006-11-16 | Korea Research Institute Of Standards And Science | Fret probes for fluorescent detection of the epsps gene |
HUE027486T2 (en) | 2005-06-23 | 2016-09-28 | Isis Pharmaceuticals Inc | Compositions and methods for modulation of SMN2 splicing |
WO2007002904A2 (en) | 2005-06-28 | 2007-01-04 | Medtronic, Inc. | Methods and sequences to preferentially suppress expression of mutated huntingtin |
EP2179737B1 (en) * | 2005-07-01 | 2013-08-14 | Index Pharmaceuticals AB | Modulating responsiveness to steroids |
EP2325315B1 (en) | 2005-10-28 | 2014-05-07 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of huntingtin gene |
US7906617B2 (en) | 2005-12-15 | 2011-03-15 | E. I. Du Pont De Nemours And Company | Polyethylene binding peptides and methods of use |
PL3210633T3 (en) | 2006-01-26 | 2019-12-31 | Ionis Pharmaceuticals, Inc. | Compositions and their uses directed to huntingtin |
WO2007123391A1 (en) | 2006-04-20 | 2007-11-01 | Academisch Ziekenhuis Leiden | Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene. |
EP1857548A1 (en) * | 2006-05-19 | 2007-11-21 | Academisch Ziekenhuis Leiden | Means and method for inducing exon-skipping |
US7855053B2 (en) | 2006-07-19 | 2010-12-21 | The Regents Of The University Of California | Methods for detecting the presence of expanded CGG repeats in the FMR1 gene 5′ untranslated region |
CN101501193B (en) | 2006-08-11 | 2013-07-03 | 普罗森那技术公司 | Methods and means for treating DNA repeat instability associated genetic disorders |
NZ574807A (en) | 2006-08-11 | 2011-01-28 | Prosensa Technologies Bv | Methods and means for treating dna repeat instability associated genetic disorders |
JP2010512304A (en) | 2006-09-27 | 2010-04-22 | メルク・シャープ・エンド・ドーム・コーポレイション | Acylated piperidine derivatives as melanocortin-4 receptor modulators |
SG166778A1 (en) | 2006-10-11 | 2010-12-29 | Max Planck Gesellschaft | Influenza targets |
WO2008103755A1 (en) | 2007-02-20 | 2008-08-28 | Mayo Foundation For Medical Education And Research | Treating cancer with viral nucleic acid |
PL381824A1 (en) | 2007-02-22 | 2008-09-01 | Instytut Chemii Bioorganicznej Pan W Poznaniu | The sequence of siRNA, vector, molecular target for siRNA reagents and vectors introduced to cells and tissues, the manner of assessment of specifity of silencing of a mutated transcript, the manner of testing of influences of RNA interference route of enz |
EP2170363B1 (en) | 2007-06-29 | 2018-08-08 | Sarepta Therapeutics, Inc. | Tissue specific peptide conjugates and methods |
CN103212085A (en) | 2007-07-12 | 2013-07-24 | 普罗森那技术公司 | Molecules for targeting compounds to various selected organs or tissues |
EP2167135A2 (en) | 2007-07-12 | 2010-03-31 | Prosensa Technologies B.V. | Molecules for targeting compounds to various selected organs, tissues or tumor cells |
US9212205B2 (en) | 2007-07-26 | 2015-12-15 | University Of Rochester | Nucleic acid binding compounds and methods of use |
WO2009023855A2 (en) | 2007-08-15 | 2009-02-19 | Isis Pharmaceuticals, Inc. | Tetrahydropyran nucleic acid analogs |
CN101896186A (en) | 2007-10-26 | 2010-11-24 | 莱顿教学医院 | The mode and the method for antagonism disorder of muscle |
WO2009099326A1 (en) | 2008-02-08 | 2009-08-13 | Prosensa Holding Bv | Methods and means for treating dna repeat instability associated genetic disorders |
WO2009101399A1 (en) | 2008-02-12 | 2009-08-20 | Isis Innovation Limited | Treatment of muscular dystrophy using peptide nucleic acid ( pna) |
EP2105145A1 (en) | 2008-03-27 | 2009-09-30 | ETH Zürich | Method for muscle-specific delivery lipid-conjugated oligonucleotides |
AU2009244013B2 (en) | 2008-05-09 | 2015-06-25 | The University Of British Columbia | Methods and compositions for the treatment of Huntington's disease |
EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
WO2009144481A2 (en) | 2008-05-30 | 2009-12-03 | Isis Innovation Limited | Conjugates for delivery of biologically active compounds |
US20110152352A1 (en) | 2008-06-10 | 2011-06-23 | Tufts University | Smad proteins control drosha-mediated mirna maturation |
GB2457965B8 (en) | 2008-07-01 | 2011-02-16 | Renovo Ltd | Methods and systems for determining efficacy of medicaments. |
WO2010006237A2 (en) | 2008-07-11 | 2010-01-14 | Alnylam Pharmaceuticals, Inc. | Phosphorothioate oligonucleotides non-nucleosidic phosphorothiotes as delivery agents for irna agents |
WO2010014592A1 (en) | 2008-07-29 | 2010-02-04 | The Board Of Regents Of The University Of Texas Sytem | Selective inhibition of polyglutamine protein expression |
US8084601B2 (en) * | 2008-09-11 | 2011-12-27 | Royal Holloway And Bedford New College Royal Holloway, University Of London | Oligomers |
US8609615B2 (en) | 2008-10-15 | 2013-12-17 | Valerion Therapeutics, Llc | Methods and compositions for treatment of myotonic dystrophy |
SI3133160T1 (en) * | 2008-10-24 | 2019-05-31 | Sarepta Therapeutics, Inc. | Exon skipping compositions for dmd |
DK2607484T3 (en) | 2008-10-27 | 2016-03-07 | Biomarin Technologies B V | Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-MRNA |
US20100248239A1 (en) | 2009-03-24 | 2010-09-30 | Mayo Foundation For Medical Education And Research | Methods and materials for detecting fragile x mutations |
EP2411532B1 (en) | 2009-03-24 | 2017-04-05 | Asuragen, Inc. | Pcr methods for characterizing the 5' untranslated region of the fmr1 and fmr2 genes |
US20120149756A1 (en) | 2009-04-10 | 2012-06-14 | Associatin Institut de Myologie | Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease |
ES2593836T3 (en) | 2009-04-24 | 2016-12-13 | Biomarin Technologies B.V. | Oligonucleotide comprising an inosine to treat DMD |
BRPI1010885A2 (en) | 2009-06-08 | 2015-09-22 | Miragen Therapeutics | chemical modification motifs for mirna and mimetic inhibitors. |
CA2931725C (en) | 2009-09-11 | 2021-10-19 | Ionis Pharmaceuticals, Inc. | Modulation of huntingtin expression |
ES2693459T3 (en) | 2009-11-12 | 2018-12-11 | The University Of Western Australia | Antisense molecules and methods for the treatment of pathologies |
US20110166081A1 (en) | 2009-12-03 | 2011-07-07 | University Of Iowa Research Foundation | Alpha-dystroglycan as a Protein Therapeutic |
WO2011078797A2 (en) | 2009-12-22 | 2011-06-30 | Singapore Health Services Pte. Ltd | Antisense oligonucleotides and uses threreof |
AU2010335039B2 (en) | 2009-12-24 | 2015-03-26 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Molecule for treating an inflammatory disorder |
WO2011097614A1 (en) | 2010-02-08 | 2011-08-11 | Isis Pharmaceuticals, Inc. | Mehods and compositions useful in diseases or conditions related to repeat expansion |
WO2011097641A1 (en) | 2010-02-08 | 2011-08-11 | Isis Pharmaceuticals, Inc. | Methods and compositions useful in treatment of diseases or conditions related to repeat expansion |
WO2012012443A2 (en) | 2010-07-19 | 2012-01-26 | Bennett C Frank | Modulation of dystrophia myotonica-protein kinase (dmpk) expression |
SI2605794T1 (en) | 2010-08-20 | 2017-01-31 | Replicor Inc. | Oligonucleotide chelate complexes |
WO2012109296A1 (en) | 2011-02-08 | 2012-08-16 | The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center | Antisense oligonucleotides |
EP3067421B1 (en) | 2011-02-08 | 2018-10-10 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
WO2012144906A1 (en) | 2011-04-22 | 2012-10-26 | Prosensa Technologies B.V. | New compounds for treating, delaying and/or preventing a human genetic disorder such as myotonic dystrophy type 1 (dm1) |
KR102339196B1 (en) | 2011-05-05 | 2021-12-15 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | Peptide Oligonucleotide Conjugates |
CA2842742A1 (en) | 2011-06-23 | 2012-12-27 | Cold Spring Harbor Laboratory | Phenocopy model of disease |
JP6317675B2 (en) | 2011-11-30 | 2018-04-25 | サレプタ セラピューティクス, インコーポレイテッド | Oligonucleotides for treating prolonged repeat disease |
US9203291B2 (en) | 2011-12-03 | 2015-12-01 | Thomas Krupenkin | Method and apparatus for mechanical energy harvesting using combined magnetic and microfluidic energy generation |
EP2790736B1 (en) | 2011-12-12 | 2018-01-31 | Oncoimmunin, Inc. | In vivo delivery of oligonucleotides |
EP2799548B1 (en) | 2011-12-28 | 2019-08-21 | Nippon Shinyaku Co., Ltd. | Antisense nucleic acid |
EP4043039A1 (en) | 2012-01-27 | 2022-08-17 | BioMarin Technologies B.V. | Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy |
WO2013120003A1 (en) | 2012-02-08 | 2013-08-15 | Isis Pharmaceuticals, Inc. | Modulation of rna by repeat targeting |
EP4400169A2 (en) | 2012-04-23 | 2024-07-17 | Vico Therapeutics B.V. | Rna modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders |
AR091065A1 (en) | 2012-05-18 | 2014-12-30 | Replicor Inc | A PHARMACEUTICAL FORMULATION THAT INCLUDES AN ANTIVIRAL OLIGONUCLEOTIDE CHELATE FOR THE TREATMENT OF AN ANTI-VIRAL INFECTION |
CA2877644A1 (en) | 2012-07-03 | 2014-01-09 | Prosensa Technologies B.V. | Oligonucleotide for the treatment of muscular dystrophy patients |
-
2008
- 2008-10-27 CN CN200880120198XA patent/CN101896186A/en active Pending
- 2008-10-27 EP EP17171389.4A patent/EP3238737B1/en not_active Revoked
- 2008-10-27 EP EP08842559.0A patent/EP2203173B1/en not_active Revoked
- 2008-10-27 ES ES08842559.0T patent/ES2564563T3/en active Active
- 2008-10-27 DK DK08842559.0T patent/DK2203173T3/en active
- 2008-10-27 AU AU2008317566A patent/AU2008317566B2/en active Active
- 2008-10-27 PT PT88425590T patent/PT2203173E/en unknown
- 2008-10-27 NZ NZ584793A patent/NZ584793A/en unknown
- 2008-10-27 CA CA2704049A patent/CA2704049A1/en not_active Abandoned
- 2008-10-27 JP JP2010530946A patent/JP5600064B2/en active Active
- 2008-10-27 ES ES13160310.2T patent/ES2639852T3/en active Active
- 2008-10-27 CN CN201610053552.8A patent/CN105641700B/en active Active
- 2008-10-27 EP EP13160310.2A patent/EP2614827B1/en active Active
- 2008-10-27 WO PCT/NL2008/050673 patent/WO2009054725A2/en active Application Filing
- 2008-10-27 HU HUE08842559A patent/HUE028662T2/en unknown
- 2008-10-27 PL PL08842559T patent/PL2203173T3/en unknown
- 2008-10-27 ES ES17171389T patent/ES2914775T3/en active Active
-
2009
- 2009-01-13 CN CN200980152464.1A patent/CN102264903B/en active Active
- 2009-01-13 NZ NZ592446A patent/NZ592446A/en unknown
- 2009-01-13 HU HUE13160338A patent/HUE027124T2/en unknown
- 2009-03-11 EP EP22203933.1A patent/EP4183399A1/en active Pending
- 2009-03-11 CN CN2009801519198A patent/CN102256606A/en active Pending
- 2009-03-11 ES ES09788170.0T patent/ES2692886T3/en active Active
- 2009-03-11 CN CN201510825064.XA patent/CN105647921A/en active Pending
- 2009-03-11 ES ES18180952T patent/ES2936464T3/en active Active
-
2010
- 2010-04-25 IL IL205322A patent/IL205322A/en active IP Right Grant
- 2010-04-26 US US12/767,702 patent/US9243245B2/en not_active Ceased
-
2011
- 2011-04-26 US US13/094,548 patent/US9926557B2/en active Active
- 2011-04-26 US US13/094,571 patent/US20110263682A1/en not_active Abandoned
-
2012
- 2012-01-16 HK HK13112417.5A patent/HK1185098A1/en unknown
-
2013
- 2013-12-04 US US14/097,210 patent/US20140113955A1/en not_active Abandoned
- 2013-12-19 US US14/134,971 patent/US20140128592A1/en not_active Abandoned
-
2014
- 2014-02-07 JP JP2014022084A patent/JP5879374B2/en active Active
- 2014-03-07 US US14/200,251 patent/US20140221458A1/en not_active Abandoned
- 2014-11-14 US US14/542,183 patent/US9528109B2/en active Active
-
2015
- 2015-02-25 US US14/631,686 patent/US9499818B2/en active Active
- 2015-10-06 IL IL241928A patent/IL241928B/en active IP Right Grant
- 2015-11-09 JP JP2015219928A patent/JP2016033140A/en active Pending
-
2016
- 2016-01-07 US US14/990,712 patent/US20160304864A1/en not_active Abandoned
- 2016-01-11 HR HRP20160025TT patent/HRP20160025T1/en unknown
- 2016-03-11 CY CY20161100214T patent/CY1117286T1/en unknown
- 2016-04-04 CY CY20161100268T patent/CY1117454T1/en unknown
- 2016-10-07 US US15/289,053 patent/US20170044534A1/en not_active Abandoned
- 2016-12-27 US US15/390,836 patent/US20170107512A1/en not_active Abandoned
-
2017
- 2017-05-12 JP JP2017095804A patent/JP6579629B2/en active Active
-
2018
- 2018-04-26 HK HK18105446.9A patent/HK1245670A1/en unknown
- 2018-06-29 US US16/024,558 patent/US10876114B2/en active Active
- 2018-08-13 IL IL261127A patent/IL261127B/en active IP Right Grant
- 2018-12-21 US US16/229,534 patent/US20190112604A1/en not_active Abandoned
- 2018-12-21 US US16/229,821 patent/US20190119679A1/en not_active Abandoned
-
2019
- 2019-02-22 US US16/283,458 patent/US20190177725A1/en not_active Abandoned
- 2019-04-25 JP JP2019084505A patent/JP6885620B2/en active Active
- 2019-09-26 US US16/584,115 patent/US11427820B2/en active Active
-
2020
- 2020-12-21 US US17/129,117 patent/US20210139904A1/en not_active Abandoned
-
2021
- 2021-05-06 JP JP2021078561A patent/JP7107622B2/en active Active
- 2021-06-23 IL IL284321A patent/IL284321B/en unknown
-
2022
- 2022-07-25 US US17/814,781 patent/US20230151362A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006000057A1 (en) * | 2004-06-28 | 2006-01-05 | SMITHKLINE BEECHAM CORPORATION, doing business as GLAXOSMITHKLINE | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
US20130211062A1 (en) * | 2010-09-01 | 2013-08-15 | National Center Of Neurology And Psychiatry | Antisense nucleic acids |
US20140315977A1 (en) * | 2013-03-14 | 2014-10-23 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11795234B2 (en) | 2018-08-02 | 2023-10-24 | Dyne Therapeutics, Inc. | Methods of producing muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide |
US11795233B2 (en) | 2018-08-02 | 2023-10-24 | Dyne Therapeutics, Inc. | Muscle-targeting complex comprising an anti-transferrin receptor antibody linked to an oligonucleotide |
US11369689B2 (en) | 2018-08-02 | 2022-06-28 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US11497815B2 (en) | 2018-08-02 | 2022-11-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US11633496B2 (en) | 2018-08-02 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US12012460B2 (en) | 2018-08-02 | 2024-06-18 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide |
US11248056B1 (en) | 2018-08-02 | 2022-02-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US11787869B2 (en) | 2018-08-02 | 2023-10-17 | Dyne Therapeutics, Inc. | Methods of using muscle targeting complexes to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy or a disease associated with muscle weakness |
US12005124B2 (en) | 2018-08-02 | 2024-06-11 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US11833217B2 (en) | 2018-08-02 | 2023-12-05 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US11844843B2 (en) | 2021-07-09 | 2023-12-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
US11986537B2 (en) | 2021-07-09 | 2024-05-21 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US11679161B2 (en) | 2021-07-09 | 2023-06-20 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11427820B2 (en) | Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA | |
EP2344637B2 (en) | Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mrna | |
AU2009310558B8 (en) | Methods and means for efficient skipping of at least one of the following exons of the human Duchenne muscular dystrophy gene: 43, 46, 50- 53. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BIOMARIN TECHNOLOGIES B.V., NETHERLANDS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DE KIMPE, JOSEPHUS JOHANNES;PLATENBURG, GERARD JOHANNES;VAN DEUTEKOM, JUDITH CHRISTINA THEODORA;AND OTHERS;SIGNING DATES FROM 20160810 TO 20160923;REEL/FRAME:048256/0844 Owner name: ACADEMISCH ZIEKENHUIS LEIDEN, NETHERLANDS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DE KIMPE, JOSEPHUS JOHANNES;PLATENBURG, GERARD JOHANNES;VAN DEUTEKOM, JUDITH CHRISTINA THEODORA;AND OTHERS;SIGNING DATES FROM 20160810 TO 20160923;REEL/FRAME:048256/0844 |
|
STCB | Information on status: application discontinuation |
Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION |